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Selected Abbreviations 
 
AbM:  Agaricus blazei Murill 
ADCC: antibody-dependent cellular cytotoxicity 
APC:  antigen-presenting cell 
BRM:  biological response modifier(s) 
CC:  cystein-cystein 
CD:  Crohn’s disease 
C(3)(4)(5): complement component (3)(4)(5) 
CR3:  complement receptor 3 
CXC:  cystein-x-cystein 
DC:  dendritic cell 
DHE:  dihydroethidium 
DHR:  dihydrorhodamine 123 
DNA:  deoxyribonucleic acid 
EC:  endothelial cells 
ELAM: endothelial cell adhesion molecule 
ELISA: enzyme-linked immuno sorbent assay 
FITC:  fluorecin isothiocyanate-conjugated 
FC:  fold changes 
Fc(r):  fragment crystalline (receptor) 
FoxP3: forkhead box P3 
GALT: gut associated lymphoid tissue 
GCOS: genechip operating software 
G-CSF: granulocyte colony-stimulating factor 
GM-CSF granulocyte-monocyte colony-stimulating factor 
GTP:  guanosine-tri-phosphate 
HLA:  human leucocyte antigen 
HUVEC: human umbilical vein endothelial cells 
IBD:  inflammatory bowel disease 
ICAM-1: inter-cellular adhesion molecule 1 
IFN:  interferon  
Ig:  immunoglobuin 
IL(r):  interleukin (receptor) 
IRAK1 Interleukin-R-associated kinase 1 
kD:  kilo Dalton 
LAK:  lymphokine-activated killer 
LAM:  leukocyte adhesion molecule 
LFA:  leukocyte function antigen 
LP:  lamina propria 
LPS:  lipopolysaccharide 
LTB4:  leukotriene B4 
MAC:   membrane attack complex 
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MBL:  mannose-binding lectin 
M cell:  microfold cell  
MCP-1: monocyte chemotactic protein-1 
MDDC: monocyte-derived dendritic cells 
MFI:  mean fluorecence intensity 
MHC:  major histocompatibility complex 
MIP-(1ß) (2): macrophage inflammatory protein (1ß) (2) 
MLN:  mesenteric lymph node 
mRNA: messenger ribonucleic acid 
MФ:  macrophage 
NADPH: nicotinamide adenine dinucleotide phosphate 
MPO:  myeloperoxidase 
NF-ĸB: nuclear transcription factor – kappa B 
NK cell: natural killer cell 
NLR:  nucleotide-binding oligomerization domain receptor 
NOD:  nucleotide-binding oligomerization domain 
PAMP:      pathogen associated molecular pattern 
PAX:  paired box  
PBS:  phosohate-buffered solution 
PE:  phycoerythrin 
PLIER: probe logarithmic intensity error 
PMN:  polymorphonuclear granulocytes 
PRM:  pattern-recognition molecule 
PRR:  pattern-recognition receptor 
RIG-1:  retionoic-acid-inducible-gene1  
RLR:  retionoic-acid-inducible-gene1-like receptor 
ROR:  retinoic acid-related orphan receptor 
ScR:  scavenger receptor 
T-bet:  T-cell specific transcription factor 
TGFβ:  transforming growth factor β 
Th cell: T helper cell 
TLR:  toll-like receptor 
TNFα:  tumor ncrosis factor α 
Treg cell: regulatory T cell 
TSLP:  thymic stromal lymphopoietin 
UC:  ulcerative colitis 
WHO:  world health organization 
XBP-1: x-box binding protein-1 
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General introduction 
 
In the coastal Piedade area outside of São Paulo, Brazil, the Agaricus blazei Murill (AbM) 
mushroom grows wildly. AbM has been used as a natural food ingredient by the locals. The 
prevalence of serious diseases like atherosclerosis, hepatitis, hyperlipidemia, diabetes, viral 
infection and cancer (40;107) was lower among people in Piedade than in the general 
population. Accordingly, this health promoting effect may be related to intake of AbM, 
which belongs to the Basidiomycetes family. AbM has many common names, such as Royal 
Sun Agaricus, Sun Mushroom, Mushroom of God, Himematsutake (japanese (jp.)), 
Songrong (chinese (zh.)) and almond mushroom. AbM grows in soils that are rich in woody 
debris, mixed woods, well-composed soils, as well as along forest-field interfaces. 
Spores of the mushroom were in 1966 taken to Japan for commercial cultivation and it 
was introduced into the health food market and later subjected especially in Asia, but also in 
Europe, to an increasing research effort (27). AbM exhibits biological effects foremost by 
interacting with cells of innate immunity including macrophages (MФ), monocytes and 
natural killer cells (NK cells). Biological consequences of AbM are anti-tumor effects in 
rodents (27;38), but also protection against allergy (22) and lethal bacterial peritonitis in 
mice (38). Studies in vitro (5;95) demonstrated that AbM stimulates the release of pro-
inflammatory cytokines from  monocytes and endothelial cells. An ex vivo study (8) showed 
a pro-inflammatory effect of AbM in whole blood by  increase  of reactive oxygen species 
(ROS) in granulocytes and modulation of adhesion  molecules also in monocytes. 
Recently, also anti-inflammatory effects of AbM have been reported (76) after rats have 
ingested this mushroom extract for several weeks, measured by reduction of nystatin 
induced rat paw oedema, reduced neutrophil migration and arthritis. Likewise, isolated ß-
glucan extract from another mushroom, Pleurotus ostreatus (69), reduced acetic acid 
induced colitis in mice when administered enterally and intraperitoneally. 
   ß-glucans are considered the most potent immunomodulatory molecules in mushrooms 
and we were interested in studying prospective anti-inflammatory effects of the AbM based 
mushroom extract in both healthy individuals and in patients with inflammatory bowel 
disease (IBD). A potential anti-inflammatory effect in patients with ulcerative colitis (UC) 
and Crohn’s disease (CD) could perhaps reduce the need for classical medication in these 
patients, which show variable effect and have side effects.         
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Composition of AbM and the mushroom extract AndoSan™ 
The mushroom extract AndoSan™  used in our experiments was obtained from the 
company ACE Company Ltd., Gifu-ken, Japan. The AndoSan™ extract is made of AbM 
mixed powder and water.  The final concentration is 340 gram per litre. It contained 82.4% 
from the mushroom Agaricus blazei Murill (AbM (jp. Himematsutake)), 14,7% from the 
mushroom Hericeum erinaceum (jp. Yamabushitake) (57) and 2,9% from the mushroom 
Grifola frondosa (jp. Maitake) (1), all belonging to the Basidiomycetes mushroom family. 
The AbM mixed powder contains per 100 gram the following constituents: moisture 5,8 g, 
protein 2,6 g, fat 0,3 g, carbohydrates 89,4 g of which -glucan constitutes 2,8 g, and ash 
1,9 g. The amount per litre of the extract for sodium was 11 mg, phosphor 254 mg, calcium 
35 mg, potassium 483 mg, magnesium 99 mg and zinc 60 mg. The content of 
lipopolysaccharide in AndoSan™ was measured to be a miniscule concentration of <0,5 
pg/ml.  
 The main component AbM is rich in ß-glucans (27) composed of ß-1,6-backbone and ß-
1-3-side branches (ratio of 1:2). However, AbM contains several active constituents other 
than β-glucans, like -(1->4)-glucans (29), proteoglucans (51), lectins (52), ergosterol 
(provitamin D2) (98), agaritine (24), isoflavonoids (71) and anti-oxidant substances (46) 
which are of most interest. Soluble AbM contains micro particles, which was confirmed by 
light microscopic examination after centrifugation in our laboratory. Thus the ß-glucan 
fraction of AndoSanTM presumably contains a continuum of small soluble to larger insoluble 
fragments. 
 
Figure 1. The medicinal mushroom, Agaricus blazei Murill (AbM) 
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 The mushroom consists of a fruiting body growing above the ground. Further more the 
fruiting body consist of a cap and a stem. The Myceliumis the vegetative part of the 
mushroom growing under the ground (Fig. 1). Depending on the manufacturers, 
accumulation of unwanted harmful chemicals in the dried mass from the fruiting body and 
the mycelium vary substantially, owing to pollution of soil by heavy metals etc. which are 
accumulated in mushrooms and fungi. Cultivated mushrooms may generate toxic 
compounds from non-toxic substrates, like agaritine (36;102), which makes up 
approximately 1% of the dried mass of the fruiting bodies. However, it is unknown to what 
extent agaritine and other phenylhydrazine derivatives from the cultivated mushrooms are 
degraded during the manufacturing procedure. Since it is generally known that heavy metals 
may be accumulated in mushrooms, it is of great importance to measure concentrations of 
such elements and to cultivate the mushroom in unpolluted soil or substrate. However, 
specialized patent-protected processing treatments can remove these substances while not 
affecting beneficial properties of this mushroom. The elements of the AbM based 
mushroom extract AndoSanTM that we used in our experiments, did not contain detectable 
Zinc (Zn), Selen (Se), Germanium (Ge) or hydrazine, according to the analysis report 
delivered by the Japan Food Research Laboratories, Tokyo, Japan.     
 
Structural and functional inter-relationship 
The cell wall of the mushroom Basidiomycetes family and other mushrooms contains 
biologically active polysaccharides, in particular ß-glucans, which are recognized as 
biological response modifiers (BRM) (58) and act on pattern recognition receptors (PRR) on 
leucocytes in both innate and adaptive immunity (25). The polysaccharide BRM, which are 
most prominently found in the fruiting bodies of mushrooms (Fig. 1), are β-glucan and -
mannan. Such polysaccharides were also found in culture medium in which AbM was 
grown (72). Since the molecular structures are mainly dependant on the osmotic and 
chemical nature of the culture medium, the methodology in obtaining a purified form of the 
active substances is very important. These polysaccharides differ in chemical composition 
especially the β-glucans (Fig. 2). β-glucan with β-(1->3)-D-linkage is usually a main water 
soluble skeleton. Three β-(1->3)-D-polymers with β-(1->6)-D-branches form a triple helical 
structure by hydrogen bonding. The triple helical structure becomes covalently bound to 
chitin, which is a major soluble polymer of the cell wall (53), rendering the resulting 
complex insoluble in an alkaline milieu. The triple helical conformation is stable at neutral 
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pH, whereas decrease in pH shifts the conformation to a single helical and furthermore, to a 
random coil structure(58). It is generally believed that the host’s immune responses to BRM 
are structurally specific. 
 Several sophisticated biotechnological methods are available for purification and 
extraction of AbM. However, the laboratory procedures do follow a few common and 
empirical methods (58;107). Briefly, the dried fruiting bodies of the mushroom is 
denaturated and detoxified by soluents/solvent (e.g. NaOH, EtOH, MeOH, Hexane, 
Chloroform) before boiling followed by additional solvents and then the freeze-drying 
process for development of a precipitate, from which active polysaccharides are isolated 
(e.g. chromatography) and tested for biological activity.  
 
Figure 2. Structure of the outer wall of fungi including -glucans. a) The cell wall is 
composed predominantly of carbohydrates that are essential for structural integrity and 
survival of these cells. b) -Glucans comprise a major component of many fungal cell walls 
and occur in linear (β-(1->3)) or branched (β-(1->6)) forms. Innermost is the bilayered cell 
membrane, which also contains sterols (ergosterol), where the glucosyl units within glucans 
which are arranged as long coiling chains of β-(1->3)-glucan-linked residues with 
occasional β-(1,6)-linked side chains. c) Three β-(1->3) chains running parallel can 
associate to form a triple-helix, and the aggregation of helices produces a network of water-
insoluble fibrils. d) Proteoglucan complex. 
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Effects of AbM in vitro, ex vivo and in vivo 
AbM stimulates macrophages in vitro (95) to increase synthesis and release of interleukin-8 
(IL-8), tumor necrosis faktor  ( TNF) and nitric oxide. In human monocytes and human 
vein endothelial cells (HUVEC), AbM induces (5) release of pro-inflammatory cytokines 
(IL-1, IL-6, IL-8, TNF), but not IL-12 or the anti-inflammatory cytokine IL-10. This 
latter result was supported by demonstrating selective up-regulation of genes for IL-1 and 
IL-8, but not for IL-10 and IL-12, by using gene expression microarray analysis of 
promonocytic THP-1 cells (leukemic cell line) stimulated with AbM (23). 
 By stimulation of whole blood with the AbM extract ex vivo (8),  expression of adhesion 
molecules CD62L (L-selectin) decreased and CD11b increased both on human monocytes 
and granulocytes. CD11b promotes complement-mediated phagocytosis in these cells. The 
level of reactive oxygen species (ROS), more specifically peroxynitrite (ONOOˉ), increased 
moderately in granulocytes, which indicated increased potential for degradation of 
microorganisms. Altogether, these results demonstrated a pro-inflammatory effect in vivo 
and ex vivo of AbM per se or combined with the two other basidiomycetes mushrooms, 
Hericium erinaceum and Grifola frondosa, in the AndoSan™ mixture. 
 AbM mycelium has also been shown to inhibit the cytopathic effect of Western equine  
encephalitis virus on VERO cells in culture (96). Moreover, in vitro bactericidal and 
fungicidal effects of Agaricus species have been reported (82;105), although our group 
earlier found none effects when examining such properties. Although, not the topic for this 
thesis, anti-tumor effects of  components of AbM have been reported in mouse models 
against fibrosarcoma, myeloma, ovarian-, lung- and prostate cancer, and in human studies 
against gynecological cancer (increased NK-cell activity and quality of life) and leukemia as 
well as in cancer cell cultures (19;98;111).  In addition to ß-glucan in AbM, ergosterol and 
agaritine also exhibit anti-tumor activity, respectively, by oral administration in sarcoma 
180 bearing mice (98) and by induction of apoptosis in leukemic cells (24). Moreover, 
isoflavonoids, another isolated subcomponent of AbM, had potent hypoglycaemic action as 
demonstrated by reduced blood glucose levels in diabetic rats (71). 
 In vivo, our group has previously reported that AndoSan™ given orally to mice before 
intraperitoneal inoculation of pneumococci (7) or feces (6), reduced subsequent degree of 
sepsis and increased survival of the mice. Increased levels of macrophage inflammatory 
protein 2 (MIP-2), the mouse analogue to human IL-8, and TNF were detected in mice 
given AbM compared with placebo prior to peritonitis, which is partly thought to contribute 
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to the improved results in the mice using this mushroom extract. This is an intriguing 
finding since MIP-2 is considered to be a pro-inflammatory cytokine.  
 Recently, the AndoSanTM mushroom extract has been shown to protect against IgE- 
mediated allergy in a mouse model when given orally either before or after subcutaneous  
sensitation of the animals (22). In supernatants of cultured spleen cells from the  
AbM-treated mice there was an increased T helper cell 1(Th1) response relative to the  
allergy-inducing T helper cell 2 (Th2) cytokine response. The observation fits with the 
 reduced specific serum IgE levels in these animals and shows that also adaptive immunity 
 is engaged by the mushroom. Since the original Th1/Th2 dichotomy (81) says that the anti 
-tumor and anti-infection Th1 response is inversely related to the Th2 response, the spleen 
 cell finding above also helps explain the concomitant anti-allergic, anti-tumor and anti- 
infection effects of AbM. Moreover, this agrees with the very interesting finding that AbM  
extract ameliorated a skewed Th1/Th2 balance both in asthma-induced and in tumor-bearing  
mice (99). 
 In line with the anti-allergic effect induced by AndoSan™ in mice, a study in 2009  
(76) where an aqueous alkaline extract of AbM was given for 1-2 weeks in mice, anti-
inflammatory effects were observed in vivo. Oral intake of AbM reduced neutrophil 
migration to the peritoneal cavity and the degree of rat paw oedema induced by nystatin as 
well as reduced the extent of arthritis induced by Freund’s adjuvant. It was speculated that 
AbM down-regulated the immune system by means of interaction with ß-glucans of the 
extract. The initial study demonstrating an anti-inflammatory effect of a mushroom extract, 
was from a ß-glucan (pleuran) isolated from the fruiting bodies of Pleurotus Ostreatus (69), 
given orally or intraperitoneally for 4 weeks in rats with experimentally acetic acid induced 
colitis. The colonic damage score was significantly reduced compared to placebo 
(cellulose). In addition, myeloperoxidase (MPO) activity was reduced in the normal mucosa 
of rats, without induction of colitis, treated solely with pleuran compared with cellulose. 
Thus, reduced MPO- activity and consequently also generation of ROS would presumably 
attenuate the acetic acid induced inflammatory response. 
 We found it intriguing, the paradoxical response of the mushroom extract being pro-
inflammatory in vitro and ex vivo, and also protective against infections. It also reduced the 
inflammatory response in vivo in rodents. One contributing factor behind the anti-
inflammation in vivo, may be the existence of low molecular weight gut absorbable 
antioxidant substances in AbM (46), which reduce the levels of ROS. 
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Mechanism for stimulation of the immune system 
The reason for the forceful and swift engagement of innate immunity when encountering an 
edible and harmless mushroom such as AbM, is its sharing of pathogen-associated  
molecular patterns (PAMP) with other highly poisonous species. Such mushrooms and 
fungi are usually a health threat due too action of their toxins; e.g. muscimol from Amanita 
muscaria and the vasoconstrictor ergotamine from Calviceps purpurea, or invasion in 
immune deficient patients (e.g. Aspergillus fumigatus) or normal individuals (e.g. 
Stachybotrys chartarum). PAMP, such as -glucans, which form the main cell wall skeleton 
in mushrooms and fungi and are their signature molecule, are recognized immediately by 
pattern recognition reseptor (PRR). More specifically, AbM acts upon cells of innate 
immunity like monocytes/macrophages (MФ) (10;39), dendritic cells (DC) (33) and NK 
(30). 
   The stimulatory effect is probably mediated by binding of foremost glucans to toll-like  
receptor 2 (TLR2), but not TLR4 (80), the dectin-1 receptor (13), the lectin binding site for 
ß-glucan of complement receptor C3 (CR3) (CD11b/18) (104) and possibly complement 
receptor C4 (CR4) (CD11c/18) (4). Stimulation of the TLR2 induced intracellular nuclear 
transcript factor kappa B (NF-ĸB) activation (Fig. 3) leads to increase of transcription and 
synthesis of mainly pro-inflammatory cytokines in vitro (103). 
 
Figure 3. The nuclear transcript factor kappa B (NF-B) pathway. Triggering TLR or IL-1R 
recruits the adaptor molecules MyD88 and IL-1R associated protein kinases, IRAKs, which 
finally translocate the NF-B into the nucleus. This transcription factor activates 
transcription of pro-inflammatory genes.  
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Since human skin endothelial cells can express all 10 TLR genes (28), TLR-binding of 
AbM was probably one mechanism behind the increased synthesis of cytokines in HUVEC, 
which demonstrated that AbM also affects endothelial cells (EC), which are important part-
takers in the innate immune response. It has also been shown that AbM affects the humoral 
immune system, a part of the adaptive immune system, through activation of factor C3 of 
the alternative complement pathway (92). The gene microarray study in AbM-stimulated 
promonocytic THP-1 tumor cells in vitro (23) also demonstrated upregulation of genes for 
TLR-2 and co-operative molecule MyD88, but not for TLR-4. This indicated that AbM 
stimulated synthesis of pro-inflammatory cytokines via interaction with TLR2. Potential 
immunomodulatory effects of AbM are depicted in the cartoon (Fig. 4). 
Fig. 4. An overview of AbM-mediated immunomodulatory effects, from ImmunoPharma.
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 The immune response 
The immune response is defined by two main components innate and adaptive immunity 
(Fig. 5). The innate immunity represents the rapidly generated process that particularly is 
represented by macrophages (M), dendritic cells (DC) and natural killer (NK) cells. 
However, minor subsets of B and T lymphocytes may also be considered as part of innate 
immunity. A unifying characteristic of these lymphocytes is that they express somatically 
rearranged receptors, like classical T and B cells, but they have limited diversity. Innate 
immune cells respond quickly to molecular patterns and present particular antigens. The 
major subtypes of cells that express pattern recognition receptors (PRR) are antigen 
presenting cells (APC), namely DC and MФ. The innate immune system does not react 
against an individual`s own cells and molecules, partly because mammalian cells express 
regulatory molecules that prevent innate immune reaction. The role of the adaptive 
immunesystem is to recognize earlier exposure and act on its presence, mainly based on T-
cells. In the adaptive immunesystem, lymphocytes are also capable of recognizing that self 
antibodies are produced and the cells producing self antibodies are killed or inactivated by 
lymphocytes. Therefore, the adaptive immune system can overreact and give rise to 
autoimmune disorders such as rheumatoid arthritis. Amongst inflammatory bowel diseases, 
Crohn’s disease and ulcerative colitis have been defined as Th1- and Th2-type autoimmune 
diseases, respectively.   
 
Fig. 5. Characteristics of innate and adaptive immunity, from Blumberg RS (9).   
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Innate immunity 
The mucosal and cellular defense 
The mucus layer outside the cellular layer entrap bacteria, and contains anti-bacterial 
peptides (e.g. -defensins) produced by Paneth cells in the crypts (55). In addition, mucus 
also contains calgranulins, IgA and lysozyme that inactivate and kill bacteria. The next 
barrier in the gastrointestinal tract is the physical barrier of the cellular layer (32;91) that is 
composed of mainly epithelial cells, but also Paneth cells and mucus producing goblet 
cells. In addition, Microfold cells or M cells, are a specialized epithelial cell of the mucosa 
that has the potential to deliver antigen from gut lumen by transcellular vesicular uptake to 
lamina propria. Another way to sample antigen across the mucosa is via membrane 
protrusions of DC both between and through the epithelial cells (17). The antigens or 
microbes will then be further processed in the lamina propria containing lymphoid tissue 
(lymph nodes and Payer’s patches) and different types of DC, lymphocytes, NK cells, MФ 
and granulocytes. A major function of DC is their migration to mesenteric lymph nodes in 
order to present a wide range of antigens to T cells, leading to either a pro- or anti-
inflammatory response. A situation of either steady state or inflammation of the intestinal 
lamina propria is shown in figure 6. 
 
Fig. 6. Steady state and inflammatory response in the lamina propria of the gut wall, from 
Coombes et al (17). 
 
 
Abbreviations: Lamina propria (LP), mesenteric lymph node (MLN)  
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 In steady state with commensally bacteria in the gut lumen DC may be conditioned by 
epithelial-cell derived factors of anti-inflammatory nature (including IL-10, tissue growth 
factor ß (TGFß), retinoic acid, thymic stromal lymphopoietin (TSLP)). IL-10 and TGFß 
may reduce the responsiveness of DC to bacterial activation signals. Confronted with the 
same stimuli, TLSP can down-regulate IL-12/23p40 production and thereby Th1 responses.  
 The acid form of vitamin A, retinoic acid, has three important functions;  
i) an enhancing effect on TGFß-mediated induction of the transcription factor called  
FoxP3, which turns peripheral T cells into Treg cells 
ii) synergy with IL-5 and IL-6 to mediate class-switching to IgA in both Peyer’s  
 patches and mesenteric lymph nodes  
iii) contribution to the DC’s ability to promote the expression of gut-homing receptors 
by lymphocytes.  
This steady state and conditioned response is characterized by the presence of a certain 
degree of Th2 cells, downregulation of Th1- and Th17 cells/effects and upregulation of the 
FOXp3 Treg cells. On the other hand, when the epithelial cells are exposed to pathogenic 
bacteria they secrete cytokines (such as IL-1, IL-6, IL-7, IL-11, and TNF), chemokine IL-8 
and granulocyte-monocyte colony-stimulating factor (GM-CSF), which creates an 
inflammatory response that may become unbalanced and create a chronic state, as seen in 
IBD. This inflammatory response is characterized by an increase of Th1 and Th17 cells and 
their cytokines. 
 
Receptors 
Toll-like receptors  
Toll-like receptor(s) (TLR), mannose receptor, scavenger receptor, retinoic-acid-inducible 
gene1 (RIG-1)-like receptors (RLR) and nucleotide-binding oligomerization domain 
(NOD) receptors are all cell membrane lined receptors. TLRs are the most important 
sensors of the innate immune system, recognizing microbes at the cell-surface. These 
receptors consist of an extracellular portion, leucine-rich repeats (LRR), which again 
consist of an N terminus and a C terminus, recognizing PAMP. The intracellular portion, 
Toll/IL-1 receptor (TIR) domains consist of Box 1-3, adapted to myeloid differentiation 
primary-response protein (MyD88). When MyD88 is recruited to the receptor complex it is 
joined by IL-1R-assosiated kinase (IRAK) and results in the activation of the NF-kB 
pathway and MAP-kinase pathway. NF-kB activation initiates transcription of several 
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genes influential on several innate immune effectors function like production of pro-
inflammatory cytokines and mediating signaling pathways to the adaptive immune system, 
B and T cells. The LRR recognize different types of PAMP, TLR1 for lipopeptides, TLR2 
for lipopeptides and peptidoglycans, TLR3 for dsRNA, TLR4 for LPS, TLR5 for flagellin, 
TLR6 for lipopeptides and zymosan, TLR7 and TLR8 for single-stranded ribonucleic acid 
(RNA), and TLR9 for CpG (cytosine-phosphate guanosine residues)-containing 
deoxyribonucleic acid (DNA) (61). Moreover, in response to fungal carbohydrate-PAMP, 
TLR2 (31) and TLR4 (64;93) have been implicated in the recognition of β-glucan and other 
polysaccharides (e.g. mannan and heteroglycan), respectively. 
 Inside the cell, in cytosol, microbial components derived from bacterial peptidoglycans 
are recognized by nucleotide-binding oligomerization domain (NOD) proteins, NOD1 and 
NOD2. NOD proteins are a part of the nucleotide-binding domain LRR-containing family 
(NLR), called inflammasomes. Inflammasomes are involved in the activation of pro-
inflammatory cytokines, IL-1 and IL-8. 
    
Dectin-1 
Dectin-1 is the primary PRR for fungal glucans and was originally thought to be a dentritic 
cell (DC) specific receptor  (dendtritic-cell-associated C-type lectin-1) (2). This receptor 
exists on many other cell types, including MΦ, monocytes, polymorphonuclear granulocytes 
(PMN) and a subset of T cells (13;101). Dectin-1 is found abundantly at the portals of 
pathogen entry (lung and intestine) (78), and its expression is influenced by various 
cytokines, steroids and microbial stimuli (109). The expression of dectin 1 is markedly 
increased by Th2 response cytokines, especially IL-4 and IL-13, whereas IL-10 and LPS 
down-regulate this expression (109). Dectin-1 specifically recognizes soluble and 
particulate β-(1-3)- and β-(1-6)-linked glucans (11;12) as well as zymosan, a stimulatory 
cell-wall extract of common yeast that is composed mainly of β-glucan, mannan, chitin, 
protein and lipids. An in vivo study in mice reported internalization of the receptor (75) on 
granulocytes and monocytes following a single injection of β-glucan which, accordingly, 
was internalized by circulating leucocytes and this effect prevailed for up to 7 days. When 
compared to β-glucans, mannan administration increased leukocyte dectin-1, thus 
demonstrating a differential effect on leukocyte dectin-1. However, MΦ internalization 
alone was not necessary to initiate an inflammatory response, but dectin-1 receptors rather 
than TLR2, were absolutely necessary for both efficient internalization of β-glucans and 
cytokine release. 
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Non-dectin-1 β-glucan receptors (other than TLR2/TLR6) and their protective roles 
Immune cells, such as NK cells and non-immune cells like EC, alveolar epithelial cells and 
fibroblasts, do not express dectin-1. But they have an important role in anti-fungal immunity 
(26) and in mediating the protective effects of β-glucans against infectious and malignant 
diseases (41;79). These cells express other receptors, like CR3 (complement receptor 3, 
CD11b/18), lactosylceremide and scavenger receptors (ScR), which can recognize certain 
carbohydrates (Table 1). Binding of -glucan to CR3 mediates, like for dectin-1, 
phagocytosis in mononuclear phagocytes. 
 The receptor binding and internalization of ligand-receptor complex prime the NF-ΚB 
translocation signaling pathways, leading eventually to the production of pro-inflammatory 
cytokines and chemokines. These in turn activate and recruit other cells to the site of 
infection, resulting in the initiation of the adaptive arm of the immune response. In the 
innate immune system, there are mainly neutrophils, M, DC and natural killer (NK) cells 
that are active in different stages in targeting different types of pathogens. Neutrophils 
constitute about 70% of blood leucocytes. These cells are short-lived (1-3 days), highly 
phagocytic and migrate across the blood vessel endothelium and into the tissue. They are 
activated by a variety of receptors like TLR receptors, lectin-, scavenger-, complement- and 
chemokine receptors. Phagocytosis is enhanced by antibody alone (via Fragment crystaline 
receptor (FcR)), complement alone (alternative pathway), antibody plus complement 
(classical pathway) or the lectin pathway (see; complement system). 
 Resting macrophages, encountering pathogens or other stimuli, will become activated 
and perform phagocytic killing of the pathogens and also produce inflammatory mediators 
to recruit other cells, e.g. IL-8 which is chemotactic factor for granulocytes. They also 
exhibit increased expression of MHC class II molecules necessary for presentation of 
antigen to T helper cells and thereby bridging innate and adaptive immunity. 
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Table 1. Pattern-recognition receptor PRR involved in fungal recognition, pathogen 
associated molecular pattern PAMP, modified from Brown GD 2006 (11)  
 
 
PRR 
 
Fungal PAMP 
CD14 Glucuronoxylomannan  
C3 Fungal surfaces 
CR3 Mannose, β-glucan, N-acetylglucosamine, methylmannoside, 
Methylglucoside, complement-opsonized pathogens 
DC-SIGN Internal mannose, terminal di-mannose 
Dectin-1 β-glucan 
Lactosyleramide β-glucan 
Mannose 
receptor 
Terminal mannose 
MBL Selected monosaccharides (such as mannose, fucose,glucose) 
Pentraxin-3 Galactomannan, zymosan 
SP-A Selected monosaccharides (such as mannose, fucose,glucose) 
SP-D Selected monosaccharides (such as mannose, fucose,glucose) 
TLR2 Phospholipomannan, zymosan, lipoproteins, lipopeptides, 
glycolipids 
TLR4 Mannan, Glucuronoxylomannan 
TLR9 CpGDNA 
Mannose 
receptor 
Mannan 
 
Dendritic cells  
DC are bone marrow-derived cells with a star-like morphology of lymphoid (including 
plasmacytoid) and non-lymphoid (monocytic) type (61). They are immature microbe-
capturing sentinels and can shift to mature cells, activating T cells by T cell receptor (CD3) 
engagement via antigen presentation on self MHC (class I or class II) located on the APC 
with costimulation (CD28-CD80/CD86 interactions). DC are the major antigen presenting 
cells within the immune system and other important groups are monocytes/MФ and B cells, 
which can present antigen captured on the B cell receptor (i.e. the F(ab)2 part of the 
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immunoglobulin molecule). The DC induces then both a primary and a secondary immune 
response and serve as an essential link between the innate and adaptive immune system 
(16). 
 In blood and peripheral tissues immature DC are constantly sampling the antigen 
enviroment. These naïve DC in the environment, produces anti-inflammatory cytokine IL-
10, which stimulates T-regulatory cells (Treg) and inhibits Th1-, Th2- and Th17 cells and 
MФ, in such a way that keeps the environment in a stable setting. With the right antigen 
stimuli, DC will change from naïve DC and become activated DC, and locally start 
secretion of a variety of pro-inflammatory mediators such as TNF-, IL-6 (also Th2 
cytokine), IL-8 and IL-12 (also Th1 cytokine). The expression of pro-inflammatory 
cytokines will attract and contribute to activation of eosinophils, macrophages, NK and 
other DC. In addition, they can kill pathogens by the production of ROS, nitric oxide and 
defensins (89). Mature DC will migrate to lymph nodes where they present antigens to T-
cells. During maturation the DC gradually increase antigen presenting capacity at the 
expense of phagocytic and cytotoxic potential. The many-sided functions of the DC 
depends on their stage of maturation and stimulation by the microenvironment which 
emphasizes the cruical role of these cells in the regulation of both the innate and adaptive 
immune response. In conclusion, major functions of DC are i) promoting innate responses, 
ii) induction of peripheral immune tolerance, iii) antigen capturing, presentation and 
processing, iv) cytokine production and v) lymphocyte activation and differentiation.   
 
Th0-, Th1-, Th2-, Th17- and Threg cells  
There are mainly two types of T-cells involved in the inflammatory process of 
inflammatory bowel disease (IBD), namely Th1 and Th2 cells. However recently, Th17 
cells  have been described as a potential new participant in IBD (50). This new lineage 
gives some knowledge to aspects which are not fully explained by the Th1/Th2 paradigm 
(54). 
 The T helper cell, CD4+ Th0 cell, is a naïve cell that requires two signals in order to 
become activated for both cellular and humoral responses. By a combination of an APC 
presenting antigen in context of their MHC molecule together with accessory molecules 
(CD28) and a particular cytokine or combination of cytokines, the naïve T-cell will develop 
into specific T-cells that can help or activate naïve B-cells to become antibody-secreting 
plasma cells that act on the specific original antigen. For the maturation towards Th1 cells, 
 22 
the naïve T-cell requires IL-12 in combination with IFNγ to activate specific signal 
transduction. Activation of transcription 1 and 4 (STAT1, STAT4) signal molecules in this 
specific signaling transcription pathway, again rapidly induces expression of T-cell specific 
transcription factor (T-bet). T-bet promotes Th1 lineage cytokines and suppress the 
development to Th2 cells. 
 T cell receptor (TCR) and IL-4R with its corresponding cytokine leads to the activation 
of STAT6, which induces the expression of the Th2 cell specific transcription factor 
(GATA-3) and enables the expression of the Th2 cytokines. GATA-3 promotes the Th2 
lineage commitment (IL-4, IL-5, IL-13, IL-10, IL-17) and suppresses Th1 developing. It is 
like a “master switch” in the maturation of naïve T cells (54). 
 The Th17 cells do not express T-bet or GATA-3 and their differentiation is initiated by 
STAT3 through IL-6, TFGβ and IL-23 (56). Both retinoic acid-related orphan receptor 
(ROR)-t and ROR are critical transcription factors necessary for the development of 
these cells. The activation of Th17 cells promote production of cytokines IL-17, IL-21, IL-
22 and IL-26. 
 Regulatory T cells (Treg) with a regulatory/suppressor function exist as various 
subpopulations within both CD4+ and CD8+ T cells. The most frequent naturally occurring 
Treg is a subset of CD4+ T cells and express CD25 (IL-2R) phenotype. 
 
Natural killer cells 
NK cells are classified as non-phagocytic large granular lymphocytes containing several 
azurophilic granules. They are capable of killing various target cells without the need of 
activation, unlike T cells that need to be activated and then need to differentiate into cells 
capable of killing. NK cells act together with DC and thereby regulate the adaptive immune 
response. NK cells act on DC via their production of IFNγ and TNF, cytokines also 
important for DC maturation. Moreover, IFNγ is important for the activation of 
macrophages and is a coercer for the differentiation of T helper cells.  
 
Reactive oxygen species (ROS) 
In the process of phagocytosis O2 is exitated and partially reduced intracellularly by the 
action of NADPH oxidase in phago-lysosomes, which gives rise to ROS like superoxide 
anion (·O2¯), hydroxyl radical (·OH), hydrogen peroxide (H2O2), and peroxynitirite 
(ONOOˉ) (100). ROS are toxic towards microorganisms, but create only a side effect 
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towards the host itself through peroxidation of lipids, proteins, nucleic acids and 
nitrosylation of proteins. ROS is generated mainly as a by-product of aerobic metabolism 
and PMN produce ROS more extensively than mononuclear phagocytes (20). The 
respiratory burst pathway which increases the production of ROS, is only induced by 
specific receptors like dectin-1 and the Fc receptors for IgG. Zymosan, which like AbM 
contain ß-glucans, induces ROS production in MФ from the bone marrow of rats (34).     
 
Adhesion molecules 
Adhesion molecules (receptors) mediate the adhesive interactions that determine the homing 
of mononuclear cells to different lymphoid organs, and facilitates PMN and monocytes 
localization to inflammatory sites (21;42). Leukocyte migration occurs usually through 
paracellular endothelial cell-cell interactions, but can also occur transcellularly. In this 
context the functions of selectins and integrins will be briefly mention, which are the major 
groups of adhesion molecules. 
 
Selectins 
Selectins have three family members; E-selectin (CD62E or endothelial cell adhesion 
molecule (ELAM)-1), P-selectin (CD62P or granule membrane protein (GMP)-140), and 
L-selectin (CD62L or leukocyte adhesion molecule (LAM)-1). Selectin-mediated leukocyte 
adhesion is an early event responsible for the leukocyte “rolling” phenomenon in 
diapedesis (37). L-selectin is expressed on most peripheral blood lymphocytes, monocytes, 
and granulocytes. Furthermore, they are expressed in spleen, bone marrow lymphocytes, 
myeloid cells, and T cells (68). They also regulate lymphocyte binding to endothelium in 
lymph node venules and thereby regulate their trafficking through the lymphoid tissue. 
 
Integrin receptor family 
Integrins plays a critical role in the regulation of cell migration, by example in, recruitment 
of leukocytes into inflamed tissues. They are large membrane proteins, consisting of an  
and a β subunit. At least 19 different integrins have been identified (86). They are further 
subclassified on the basis of structurally distinct β chains. The members of the β2 subfamily 
(also known as leukocyte integrins or leukointegrins), are composed of three distinct 
molecules, designated as leukocyte function antigen-1 (LFA-1), Mac-1 and gp150,95. The 
members of the β2 subfamily β2 leukocyte integrins, have been classified according to their 
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 and β subunits as CD11/CD18 molecules by the World Health Organization (WHO). 
They are composed of identical β subunits (CD18) and different  subunits (CD11a for 
LFA-1, CD11b for Mac-1, and CD11c for gp150,95). Molecular expression of β2 integrins 
on phagocytes is up-regulated when the cells are stimulated by chemotaxins (C5a, LTB4) 
and cytokines (TNF). Thus, the expression of integrins on phagocyte surfaces help in 
locating to circulating cells to the sites of tissues injury and in the host defense against the 
invaders (67). 
 
Complement system 
The chemical defense mechanism of the immunesystem includes the complement system 
and cytokines. The complement system can be activated by three different pathways. The 
classical pathway is activated by certain antibodies (IgM, IgG) bound to antigens, whilst 
the alternative pathway and the lectin pathway are activated by the innate immune system. 
The alternative pathway is activated by binding to components on the microbial 
polysaccharides or endotoxin from the cell membrane of Gram-negative bacteria, yeast or 
protozoa. In Gram-positive bacteria the alternative pathway is activated by teichoic acid 
from the cell-wall. The lectin pathway is activated  by the binding of plasma mannose-
binding lectin (MBL) to mannose residues on proteins in microbes, but not on mammalian 
molecules. 
 The function of the complement system is:  
i)  triggering and amplification of inflammatory reactions 
ii) attraction of phagocytes by chemotaxis 
iii) clearance of immune complexes 
iv) cellular activation 
v)  direct killing by lysis of invading microorganisms 
vi) important role in development of antibody responses 
  
 All three pathways ends in activation of C3 and compromise a proteolytic cascade 
creating new complement complexes which cleave other complement proteins. The 
activation cascade ends with three major complexes: 
i) C3a and C5a, small chemotactic and and anaphylactic fragments 
ii) C3b and C4b, large opsonic fragments 
iii) C5b-9n, membranolytic membrane attack complex 
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Cytokines  
Cytokines are small and low molecular weight proteins (8-75 kilo Dalton (kD)) synthesized 
by leukocytes and mediate signaling between these cells. They are both regulatory and 
effector molecules and are often  classified into interleukines, interferons, chemokines and 
leukocyte growth factors. The function of the cytokines examined in this study will be 
presented (61).  
     
Interleukin 1ß 
Pro-inflammatory IL-1ß is produced following infection or injury by mainly mononuclear 
phagocytes and DC, often in synergy with TNF (73). Immunologically activated T-cells, 
immune complexes, complement 5a (C5a) and interferon γ (IFNγ) can stimulate IL-1ß 
production. LPS from gram-negative bacteria is the major stimulant for production of IL-1ß. 
From the cell walls of Gram positive bacteria, exotoxins and from the cell walls of the yeast, 
zymosan, exotoxins and zymozan can influence the production of IL-1ß.This inflammatory 
cytokine can up-regulate host defenses and function as an immunoadjuvant. Crucial effects 
of IL-1ß are CD4+ T-cell proliferation by inducing IL-2 release, promoting B-cell growth 
and differentiation, inducing IL-6 synthesis and enhancing leukocyte-endothelial adhesion. 
IL-1ß activates T cells and in association with IL-4, B cells are activated partly by induction 
of IL-6, which is a B cell differentiation factor. Along with TNF, IL-1ß -mediated 
induction of IL-6, induces hematopoietic growth factor production by fibroblasts, EC, and 
bone marrow stromal cells. The cytoplasmic structural domains of TLR are nearly identical 
to those of IL-1ß receptors. Furthermore, the IL-1RI and cytosolic Toll protein have similar 
gene organization and aminoacid homology, and trigger similar signaling cascades. In 
humans, IL-1ß produces fever, headache, myalgia and athralgia. IL-1ß increases the 
expression of adhesion molecules of EC which cause increased adherence of neutrophils, 
monocytes, and lymphocytes. IL-1ß induces several transcription factors, especially NF-ΚB 
and also is a hepatocyte stimulating factor as shown by increased production of acute phase 
proteins (47).  
 
Tumor necrosis factor  
TNF and IL-1ß synergistically act in the inflammatory process and exhibit mainly 
overlapping effects. Infections, trauma, ischemia, immune-activated T cells, toxins, IL-1ß 
and TNF initiate the cascade of inflammatory mediators by targeting EC, and inducing the 
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expression of cell membrane adhesion molecules such as intrinsic cell inter-cellular 
adhesion molecule (ICAM)-1. TNF exerts in vivo toxic effects on cells demonstrated by 
the damage to tumors and blood vessels, but also induces release of chemokines and 
activates phagocytosis. Apoptosis is induced by TNF through binding to its corresponding 
receptor which activates intracellular signals leading to programmed cell death. It is secreted 
mainly by mononuclear phagocytes, but also by T- and B cells and NK cells. One of its 
main functions together with the related cytokines is to activate the transcription of NF-κB, 
which has been described to be the master-switch of the immune system. Anti-TNF is used 
in treatment of IBD, foremost in CD. Previously TNF was known as cachectin and has 
recently been found to play a major role in cachexia together with IL-6 in driving the 
inflammation that is believed to be the background for this syndrome. 
 
Interleukin 6 
IL-6 is a pleiotropic type-2 pro-inflammatory cytokine which along with IL-1ß, mediates 
multifunctional host responses and regulates development of multiple cell types. Its role as 
a regulator, directing a shift from innate to adaptive immunity, is achieved through 
differential control of leukocyte recruitment, activation and apoptosis. It is crucial for the 
synthesis of acute phase proteins in the liver, mucosal production of IgA and the fever 
response during inflammation. IL-6 also stimulates the pathogen clearance function of 
neutrophils. In adaptive immunity IL-6 appears to have a major influence on end stages of 
B cell differentiation. However, in chronic inflammation like IBD and rheumatoid arthritis, 
IL-6 exhibits harmful events and inhibition of IL-6 signaling improves symptoms in 
arthritis patients (59). IL-6 is produced by activated monocytes, MΦ, EC, activated T-cells 
and liver cells in response to IL-1ß and TNF. This activation occurs by IL-1ß and TNF 
binding to a membrane bound receptor complex (glycoprotein, gp130 and IL-6R) and via 
naturally occurring soluble IL-6R (48).   
 
Chemokines (IL-8, MIP-1ß, MCP-1) 
Chemokines are produced as a result of acute inflammation and are known as chemotactic 
and activating factors of leukocytes. The primary immune function of chemokines is to 
mediate selective trafficking of leukocyte subsets between blood and various tissues and the 
recirculation of lymphocytes between the tissues and lymphatics for immune surveillance. 
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 The cystein-x-cystein (CXC) chemokine, IL-8 acts predominantly on neutrophils and has 
lesser impact on monocytes and lymphocytes. Particularly good sources for IL-8 production 
are monocytes, EC, but also fibroblasts. Effects on in vitro stimulation of neutrophils 
include induction of shape change, respiratory burst with generation of superoxide and 
H2O2, release of lysosomal enzymes, generation of bioactive lipids and up-regulation of 
adhesion molecules. Transendothelial migration of neutrophils is further enhanced by down-
regulation of cell-bound L-selectin by shedding (94). IL-8 also stimulates the activation and 
mobility of T-cells, eosinophils, basophiles and monocytes. In unstimulated EC, IL-8 
increases the adhesion of neutrophils, whereas preactivated EC with IL-1, TNF, and LPS 
inhibits this phenomenon (85). In B-cells, IL-8 inhibits IL-4 induced IgE production. In 
humans, two distinct receptors (IL-8A and B) for its analogue IL-8 have been identified and 
are coupled to guanosine-tri-phosphate (GTP)-binding proteins (15). 
 The cyctein-cystein (CC) chemokines include macrophage inflammatory protein-1ß 
(MIP-1ß) and monocyte chemotactic protein-1 (MCP-1), attract mostly monocytes and T 
cells with lesser effects on basophiles and eosinophils. In general, neutrophils are 
unresponsive to the group of CC chemokines. MIP-1ß also selectively attracts CD4+ cells, 
but not CD8+ cells. MIP-1ß acts on Th1 cells and M by binding to the chemokine receptor 
CCR5. MCP-1 acts on the chemokine receptor CCR2 and chemoattracts and activates 
mainly monocytes, but also Th2 cells acting on T cells, NK cells, basophiles and immature 
DC. The human CC chemokines are made primarily by activated T cells and DC. 
 
Interleukin 2 
The vast majority of IL-2 is produced by Th1 cells that have been activated by a foreign 
antigen and stimulated with IL-1ß. Its main function is to enhance proliferation of activated 
Th1 cells (CD4+/CD8+) as an autocrine feedback mechanism, but also function as a 
chemoattractant for T-cells. Moreover, IL-2 enhances monocyte responses and stimulates 
B-cell proliferation and antibody production as well as proliferation of NK-cells. 
Synergism of IL-2 and IL-12 induces production of interferon  (IFN) and TNFα in NK-
cells, which then develop into lymphokine-activated killer (LAK) cells. Unlike other 
cytokines, IL-2 is crucial for induction of self tolerance as evidenced by development of 
hemolytic anemia and chronic IBD in animals lacking IL-2 and IL-2 receptor (61). In 
humans two low affinity receptors for IL-2 exist, IL-2Rß and IL-2R, where binding of IL-
2 yields low levels of signaling and further differentiation.        
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Interleukin 17 
Interleukin-17 is mainly produced by the “new member” of T-helper cells, Th17 cells, but 
also by NK cells. The Th17 cells also produce IL-21, IL-22 and IL-26 (in humans) which 
function in synergy with IL-17. IL-17 acts on stromal cells such as keratinocytes, 
fibroblasts, epithelial cells and EC and stimulates them to secrete IL-6, IL-8 and G-CSF. 
Injection of IL-17 into mice induces IL-6-dependent increase in blood neutrophils and such 
mice are also resistant to virulent bacterial infections (61). High levels of IL-17 have been 
found in synovial tissue of patients with rheumatoid arthritis. Studies suggest that IL-17, 
especially at mucosal sites, plays a role in protection against both extracellular and 
intracellular bacterial and fungal infections (e.g. Aspergillus and Candida) (18). This 
protection is partly mediated through the generation of G-CSF and some CXC chemokines 
(54) which recruit neutrophils to the inflammatory site. IL-17 together with IL-22 can also 
augment the secretion of anti-microbial peptides. Examples of extracellular and intracellular 
infections studied are caused by S. aureus, K. pneumonia and M. pneumonia, S. 
typhimurium, respectively. Inadequate levels of Th17 cytokines, IL-17 included on the other 
hand, can result into excessive inflammatory responses with tissue destruction found in 
autoimmune diseased like rheumatoid arthritis and IBD (74). This “new” Th17 cell lineage 
offers many explanations to a porly understood area in host immunity not fully explained 
previously by the Th1/Th2 paradigm. IL-17 is evolutionary conserved and the gene exists in 
molluscs, which existed in ancient times before the development of the adaptive T-cell 
immunity, linking innate and adaptive immunity (54).  
 
Interferon   
Regardless of the types of interferon, their two major functions are antiviral activity and 
anti-proliferative activity. INF is mainly produced by activated Th1-cells and to a lesser 
extent by cytotoxic T-lymphocytes and NK cells. It activates MФ to synthesize 
inflammatory cytokines such as TNFα, IL-1ß, IL-12 and is also responsible for intracellular 
generation of anti-microbial nitric oxide and ROS. Other activities of IFN are induction of 
expression of Fc receptors suitable for complement-mediated destruction and antibody-
dependent cell-mediated cytotoxicity of tumor cells and microbes, the latter performed by 
NK cells. In the adaptive immunity INF up-regulates both major histocompatibility 
complex (MHC) class I and II expression on a wide variety of cell types. Because of its 
effect on synthesis of both IL-12 and IL-18 in MФ and reduction of IL-4 synthesis in naïve 
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Th0 cells, Th1differentiation relative to Th2 differentiation is favored. The consequence is 
an immune response best-suited for fighting intracellular pathogens (e.g. virus). The IFN-
R is expressed on all cell types except erythrocytes. 
 
Interleukin 12 
IL-12 is a large disulfide-linked heterodimer composed of p35 and p40 subunits, which is 
unusual for cytokines. It is primarily synthesized by MФ, but to some extent also by 
neutrophils, DC, monocytes and B cells. IL-12 plays a key role in the immune response by 
linking to MФ and DC and thereby activate them for microbial ingestion. The innate 
response is activated through an NK cell activation which further differentiates naïve Th0 
cells into Th1 cells. IL-12 is the major cause of IFN production by NK cells and Th1 cells, 
which is crucial for host defense against intracellular pathogens, including replicating 
mycobacteria. The Th1-cell response promoted by IL-12, gives rise to stimulation of 
antibody enhancement of isotypes IgG2a, IgG2b and IgG3, but not Th2 associated IgG1 
and IgE. IL-12 may play a role in CD, which in part is considered a Th1-cell disorder. The 
high affinity IL-12Reseptor is expressed primarily on activated T- and NK-cells, but also 
by DC and B cells.  
 
Interleukin 4 
IL-4 is a powerful pleiotropic Th2 cytokine, which is mainly synthesized by CD4+ T-cells, 
but also by basophiles, mast cells and influences all cell types through IL-4R. Key activities 
of IL-4 include differentiation of Th0- into Th2 cells, stimulation of B cells to synthesize 
IgE and IgG1, but not IgG2a, IgG2b and IgG3. IL-4 stimulates IL-12 synthesis in MФ and 
DC, which also functions as a negative feedback mechanism for the Th2 cell response 
(increased production of IL-4, IL-5, IL-10 and IL-13). Moreover, increased IL-12 synthesis 
of MФ and DC inhibits synthesis of TNFα and IL-1ß as well as adhesion molecules. Mast 
cells are stimulated to proliferation and degranulation which is important in allergic 
responses. IL-4 is also important for defense against helminth worms because the generated 
IgE binds to eosinophils via their fragment crystalline (Fc) receptors to carry out efficient 
antibody-dependent cellular cytotoxicity (ADCC). IL-4 effects are generally antagonistic to 
those of IFN-.   
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Interleukin 13        
This cytokine is produced by activated T cells, in particular Th2 cells, but also basophils 
and mast cells. Except from differentiation from Th0 into Th2 cells, IL-13 exhibits similar 
activities to IL-4, but the response is smaller in magnitude. IL-13 inhibits synthesis of pro-
inflammatory cytokines (IL-1ß, IL-6, TNF and IL-8) in MФ, but phagocytosis is not 
blocked, whereas antibody-dependent cellular cytotoxicity (ADCC) is reduced. IL-13 
stimulates proliferation of B cells and their isotype switching to increased production of 
IgE. As for IL-4, IL-13 signaling at least in mice, is required for defense against parasites 
(nematodes).    
 
Interleukin 10 
IL-10 has either immunosuppressive or immunostimulatory effects on various cell types. 
The major producers of IL-10 are activated monocytes, MФ and Th2 cells, but also DC, B 
cells, eosinophils, mast cells, keratinocytes, hepatocytes and other cell types as well. The 
main function of IL-10 is to tune down inflammatory responses by targeting mainly 
monocytes, MФ, neutrophils, eosinophils and mast cells. The immunosuppressive role is by 
enlarge effectuated by inhibiting pro-inflammatory cytokines through inhibiting NF-ĸB-
activated transcription of genes encoding particularly for TNFα, IL-1β, IL-6, IL-8 and IL-
12. Therefore, IL-10 plays an important role for the down regulation of the massive 
cytokine release occurring during septic shock. The respiratory burst and ROS dependent 
killing of microbes by MФ is also inhibited by IL-10. As for the immunostimulatory effect, 
IL-10 promotes a Th2 cell response by inhibiting secretion of IFN and IL-2 by Th1 cells. 
The two receptors for IL-10, IL-10R1 and IL-10R2 are expressed mainly on hematopoietic 
cells.  
 
Interleukin 5   
IL-5 is a homodimeric cytokine of particular importance for eosinophil differentiation, 
activation and chemotaxis. Moreover, IL-5 stimulates histamine release from mast cells and 
IgA synthesis in B cells as well as proliferation and differentiation of cytotoxic T 
lymphocytes. These effects can lead to eosinophilia and induction of asthma, but also   
increased cell-mediated immunity in the battle against parasitic infection. IL-5 is produced 
primarily by Th2 cells, and to a lesser extent by activated mast cells, eosinophils, NK cells 
and B cells.  
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Interleukin 7  
IL-7 promotes lymphopoiesis and development of B-cells and T cells and is also important 
for generation of memory T cells. This cytokine is produced mainly by stromal cells in the 
bone marrow and thymus, but also by B cells, monocytes, MФ, keratinocytes and intestinal 
intraepithelial lymphocytes.    
 
Colony stimulating factors     
These factors are divided into granulocyte colony-stimulating factors (G-CSF) and 
granulocyte-macrophage colony-stimulating factors (GM-CSF). Both are mainly produced 
by stromal cells, mononuclear phagocytes, EC, activated T cells and fibroblasts. G-CSF 
stimulates development and recruitment of leukocytes from bone marrow to blood. It is used 
for recruitment of CD34+ hematopoietic stem cells from bone marrow to blood when 
harvesting such cells for later use in stem cell transplantation for bone marrow rescue after 
high-dose chemotherapy in cancer treatment. GM-CSF stimulates growth and differentiation 
of colonies from pluripotent hematopoietic stem cells, into neutrophils, eosinophils, 
basophils monocytes, megakaryocytes and erythrocytes.  
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Inflammatory bowel disease 
In the past, inflammatory bowel disease (IBD) was almost impossible to distinguish from 
infectious disease of the gastrointestinal tract. The designations ulcerative colitis (UC) and  
Crohn’s disease (CD) were presented in 1888 and 1932, respectively. Since the 1960s the 
term IBD has been used mainly for UC and CD that affects both sexes and mostly in the age 
group from 15-35 years. UC affects the mucosa whilst CD affects all layers of the intestinal 
wall of the large and small bowel. In UC there may be a continuous inflammation in the 
colon and microscopically the entire colon is often affected. In CD, healthy and diseased 
patches of bowel are often interspersed. In Nordic countries the incidence of UC is about 
10-15 per 100.000 and 5-8 per 100.000 for CD. The diseases are characterized by chronic or 
relapsing inflammation that may cause anorexia, weight loss, diarrhea, pain and fever. In 
CD, malabsorption and subileus occurs from small bowel stenosis. The transmural 
inflammation can cause fistulization to other epithelial lined organs. Extraintestinal 
autoimmune manifestations like iridocyclitis, spondylitis and painful and inflamed joints 
also occur with a preponderance in CD. The development of IBD is thought to originate 
from a combination of genetic and environmental factors (89) (Fig. 7).  
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Fig. 7. Genetic and environmental factors influencing the homeostasis of the bowel mucosa 
(from Sartor RB (89)). 
 
 
 
Examples of genetic aberrations that reduce host defense to bacteria are i) mutation of 
transcription factor x-box binding protein 1 (XBP-1) necessary for secretory function of 
intestinal epithelial cells and Paneth cells (e.g. anti-microbial peptides) and ii) mutation of 
nucleotide-binding oligomerization domain (NOD)2 resulting in reduced bacterial clearance 
by phagocytes. In IBD, environmental factors contribute to dysbiosis or abnormal bacterial 
composition of the gut, which predisposes for disease development. The diversity of 
bacteria has been found to be decreased in IBD. However, simultaneously there is an 
increase of mucosa-associated pathogenic bacteria like enterobacteria, including adherent 
and invasive E. coli, but also decreased clostridial bacteria, like protective Faecalibacterium 
prausnitzii. Reasons for disease contributing dysbiosis can be i) lack of transferral of 
maternal bacteria like Lactobacilli and Bifidobacteria conveyed by vaginal delivery and 
breast feeding, ii) aberrant composition of diet and iii) repeatedly use of antibiotics 
(combinations of ciprofloxacine, metronidazole and amoxicillin). 
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 One hypothesis is that the disease process in the mucosa and lamina propria 
characteristically for UC is Th2 cell driven, and for CD is Th1 cell and Th17 cell driven 
(Fig. 8). Accordingly, modulation of these cytokines and following cellular responses 
towards conditioning and a steady state situation (Fig. 6 and 8) may be a therapeutic target 
(63). 
 
Fig. 8. Potential cytokine profiles in UC and CD (from Melmed GY, et al. (63)). 
 
Abbreviations: ICAM1/VCAM1/MadCAM1 (adhesion molecules), NLR (node-like 
receptor(s)), TL1A (member of family of TNF (tumor necrosis factor)), CTLA4 (cytotoxic 
lymphocyte-associated-protein 4). 
 
 Calprotectin, an abundant cytosolic protein in neutrophils (97), can when released to 
feces  (83;106) be used as a sensitive and particularly suited surrogate marker for disease 
activity in IBD. 
 For patients with UC and CD an unselective increase in the colon mucosa of chemokines  
(MIP-1ß, MCP-1 and IL-8) (3) and cytokines IL-1ß (60), IL-6 and TNF (110) have been 
demonstrated.  In serum, however fewer cytokines are studied, but increased levels of IL-6 
(44) and TNF (62;66) were detected in both UC and CD, whilst increased MIP-1ß was 
found  in a former disease of UC (90). Accordingly, more studies on levels of cytokines in 
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these patients are warranted. Granted that cytokine levels in blood mirror those of the gut 
wall, we chose to study cytokine levels in blood instead of in gut mucosa for three reasons. 
Firstly, blood cytokines are much easier accessible than gut located cytokines. Secondly, the 
representativity of a blood sample presumably is better than hitting the hot spots of disease 
within the mucosa of the long gut. Thirdly, endoscopy with biopsies may imply a 
bothersome and risky procedure (e.g. bleeding and perforation) for the patients.  
 
Methodological considerations 
Ethics 
Written informed consent was obtained from all participants of the study, which was 
approved by the local ethical committee.  
 
Multiplex cytokine assay 
We used the multiplex bead-based sandwich immunoassay technology (Luminex, Austin, 
TX, USA) and a human cytokine 17-plex kit (Bio-Rad laboratories, Hercules, TX, USA), 
strictly following the manufacturers’ instructions, to measure the concentrations in 
individual heparinized plasma samples of the following cytokines, chemokines and growth 
factors (lower detection limits (in pg/ml) in parentheses); IL-1β (2.0), IL-2 (1.2), IL-4 (0.3), 
IL-5 (2.3), IL-6 (2.1), IL-7 (3.0), IL-8 (1.6), IL-10 (1.8), IL-12 (3.0), IL-13 (0.9), IL-17 
(2.5), G-CSF (1.9), GM-CSF (0.8), IFNγ (2.0), MCP-1 (1.7), MIP-1β (2.0) and TNF-α (5.4). 
Briefly an explanation of the technique, 25 μl of polystyrene micro beads (diameter 5.6 μm) 
coated with specific antibodies are added to each well. Then 100 μl of the sample is added 
and incubated for 3 h at room temperature on a horizontal orbital microplate shaker, prior to 
washing of the beads three times. Then 50 μl of biotinylated human antibody is added to the 
wells and incubated likewise for 1 h at room temperature. The biotin labeled human 
antibody binds to the analyte bound to the bead bound capture-antibodies. After washing of 
the beads to remove free antibody, 50 μl of streptavidin-PE fluorescent dye is added to the 
well and incubated likewise for 30 min at room temperature followed by washing of the 
beads. Streptavidin-PE binds to the biotinylated human antibody that again binds the 
corresponding antigen which is further bound via another epitope by the captured antibody 
that is linked to the bead.  Finally, 100 μl of wash buffer is added to the wells during 
shaking and fluorescence signals, as measure of cytokine concentrations, are measured 
during 90 min using the Luminex analyzer	. The advantages of this method is mostly the 
 36 
possibility to analyse precisely multiple cytokines in a small sample volume (100 μl), but 
also from its high sensitivity for detection of cytokines at levels of a few pg/ml. 
 
Flow Cytometry 
Flow cytometry is a rapid measurement technique used in laboratories worldwide, 
employing a fluid stream to carry cells through a detection counter unit. It is used to 
measure the relative fluorescence, size and granularity of individual cell particles in a 
moving suspension. Flow cytometry is also referred to as fluorescence-activated cell 
scanning or sorting, which can be used to harvest special cell types. We have applied this 
technique to measure the expression of adhesion molecules, using fluorecin isothiocyanate 
conjugated (FITC)- and phycoerythrin (PE)-conjugated monoclonal antibodies against 
CD11b, CD11c, and CD62L, and ROS in human leukocytes (8). The intracellular free 
radical species produced by the respiratory bursts were detected by two different probes, 
namely; the dihydroethidium (DHE) probe (mainly reflects superoxide anions) and the 
dihydrorhodamine 123 (DHR) probe (mainly reflects peroxynitrite ions). The production of 
ROS in leukocytes could be evaluated due to the transformation of the DHE/DHR probes 
from non-fluorescent to fluorescent compound by the oxidative burst intermediates within 
the cells. The results were always calculated as mean fluorescence intensity (MFI) of 10 000 
cells. This method was also used when monocyte derived DC, after detaching from the cell 
wells, were labelled with FITC- or PE-labeled mouse monoclonal antibodies to markers 
CD1a, CD14, CD45/14, CD40, CD80, CD86 and isotype controls (IgG1,ĸ and IgG2b,ĸ), 
prior to analysis of fluorescence intensity of the DC by flow cytometry. 
 
Microarray analysis 
Studies on gene expression by microarray analysis (www.affymetrix.com) were performed 
in IBD patients and in three healthy volunteers. Blood was harvested in paired box (PAX) 
gene tubes specifically designed to preserve RNA from blood for microarray experiments 
prior to (day 0) and after (day 12) of  consumption low dose (60 ml/day) of AndoSanTM in 
IBD patients and prior (day 0) and after (day 2) of consumption high dose (360 ml/day) of 
AndoSanTM. The PAX gene tubes were frozen and kept at -20 ºC until extraction with the 
PAXgene Blood RNA Kit (Qiagen) according to the manufacturer’s recommendation.  2.5 
µg of total RNAs were subjected to One Cycle cDNA Synthesis Kit following the 
manufacturer´s (Affymetrix) recommended protocol for gene expression analysis. 
Biotinylated and fragmented  cRNA (15 µg) was hybridized to the Affymetrix HG U133 
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Plus 2.0 Array,  representing 47000 transcripts  for 38500 well-characterized human genes. 
The signal intensities were detected by Hewlett Packard Gene Array Scanner 3000 7G 
(Hewlett Packard, Palo Alto, CA). The 6 scanned images were processed using Affymetrix 
genechip operating software (GCOS) 1.4. The CEL files were imported into Array Assist 
software (v5.2.0; Iobion Informatics LLC, LaJolla, CA) and normalized using the Probe 
Logarithmic Intensity Error (PLIER) algorithm in Array Assist to calculate relative signal 
values for each probe set. In order to filtrate for low signal values, the MAS5 algorithm in 
Array Assist was used to create a dataset of Absolute Calls, showing the number of present 
and absent calls for each probe set. The filtration was performed by eliminating probe sets 
containing ≥4 absent calls across the data set, resulting in a reduction of probe sets from 
47,000 to 28,188. For expression comparisons of different groups, profiles were compared 
using paired t-test. The results are expressed as fold changes (FC), e.g. ratio of the mean 
signals between consumption of high dose AndoSanTM  for 2 days and immediately prior to 
AndoSanTM consumption. Gene lists were generated with the criteria of p<0.05 and FC of 
≥|2|. 
 
Experimental design 
Ex vivo experiments. Heparinized blood was collected from healthy volunteers who denied 
smoking and use of any medication. This blood was immediately incubated with 0.1%, 
0,5%, 2,0%, 5,0%, 10,0% or 15,0% of sterile AndoSan™ for 6 h at 37 °C. Plasma was then 
harvested and frozen until analyzed for cytokines, chemokines and growth factors (paper I). 
 In vivo experiments. Ten healthy individuals volunteered to participate in the study of 
oral intake of low dose (20 ml thrice daily) or high dose AndoSan™ (120 ml thrice daily) 
for 12 and 2 days, respectively. The dose of a total of 60 ml of the mushroom extract per 
day was chosen as this was the dose recommended by the manufacturer. Participants were 
asked to avoid mushroom-containing foods for 3 days prior to and during the experimental 
period. In the low dose experiment, the harvested blood from the participants was also 
incubated with LPS (1 mg/l) ex vivo, in order to boost the release of leukocyte derived 
cytokines (papers I and IV). Twelve  patients with UC and patients with CD, respectively, 
ingested likewise the low dose AndoSan™ for 12 days, and were analysed for the same 
parameters in blood. In additon, the IBD patients were also analysed for amount of the 
inflammatory marker calprotectin in blood and feces (paper IV). Ten healthy individuals 
were tested for expression of ROS and adhesion molecules (CD11b, CD11c, CD62L) prior 
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to day 0 and during days 1, 2, 5, 8, 12 consumption of low dose (20 ml thrice daily) 
AndoSan™. Gene expression by microarray analysis in 15 healthy individuals were 
examined prior to (day 0) and after two days (day 2) intake of high dose (120 ml thrice 
daily) AndoSan™ (paper III). 
  In vitro experiments. Human monocytes were isolated from buffy coats from blood 
using a modified version of Sallusto’s procedure (88), cultured in vitro and differentiated 
into DC by incubation with IL-4 and GM-CSF for 6 days, with replenishment of the culture 
medium at day 3. The monocytes were at day 6 differentiated into monocyte-derived DC as 
determined by flow cytometry assay of DC-specific surface markers (HLA DR, CD1a, 
CD40, CD45, CD80, and CD86, but not CD14) (77). During further experiments with the 
cells, IL-4 and GM-CSF was kept in the medium to prevent the cells from reverting to 
monocytes. The synthesis and release of cytokines were studied upon stimulation with 
different consentrations of AbM (paper II).  
 
End points 
The levels of the various parameters in the human studies (papers I and IV) before and after 
intervention with AbM were compared and tested for statistical differences. Likewise, the 
levels of cytokines studied were tested relative to before and after AbM stimulation. 
 
Statistical analysis 
Data are presented as mean and standard error of mean (SEM) or median (range) values 
comparing cytokines, calprotectin and different blood samples as a consequence of AbM 
stimulation. Non-parametric Wilcoxon’s paired sample test was used to compare parameters 
from two different time-points. Analysis of variance (ANOVA) for paired data with Dunn’s 
multiple comparisons was used for multiple comparisons of continuous variables. Pearson’s 
product correlation was used for dose-responses. Instat for Windows™ statistics software 
package (Graphpad Software, San Diego, CA, USA) was used. P values below 0.05 were 
considered statistically significant. 
 
Aims of the study 
AbM exhibits pluripotent potential by stimulating cells of the innate immune system. 
Anti-tumor, pro-inflammatory, anti-allergic and even anti-inflammatory effects in 
rodents have been reported. However, whether AbM in humans may have an anti-
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inflammatory effect has not been studied. Such an effect would particularly be of 
interest to further investigate in patients with IBD.    
   The first aim was to explore AbM`s effect in healthy individuals and in patients 
with IBD. 
   The second aim was to investigate the effect of AbM in vitro on the antigen 
presenting DC that bridge innate and adaptive immunity.  
   The third aim was to study the effect of AbM in vivo on expression of adhesion 
molecules and ROS in healthy individuals on and in patients with IBD.   
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General summary 
 
Paper I: 
In this paper we wanted to study the effect of cytokine release in healthy volunteers 
ingesting the mushroom extract Agaricus blazei Murill (AbM) for several days. AbM has 
been shown to stimulate mononuclear phagocytes in vitro to produce pro-inflammatory 
cytokines, and to protect against lethal peritonitis in mice. After stimulation of whole blood 
ex vivo with 0.5–5.0% of a mushroom extract, AndoSan™, there was a dose-dependent 
increase in all the 17 cytokines studied (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-
12, IL-13, IL-17, G-CSF, GM-CS , IFNγ, MCP-1, MIP-1β and TNF-α), ranging from two to 
399-fold (TNFα). In the eight volunteers who completed the daily intake (60 ml) of AbM 
extract for 12 days there was a significant reduction in vivo in levels of IL-1β (97%), TNF-α 
(84%), IL-17 (50%) and IL-2 (46%). In fifteen volunteers who completed an intake of 120 
ml thrice daily for two days,  there was a trend towards reduction of MIP-1β, MCP-1,IL-6 
and IFNγ. We concluded that the discrepant results on cytokine release ex vivo and in vivo 
may partly be explained by the antioxidant activity of AbM in vivo and limited absorption of 
its large, complex and bioactive β-glucans across the intestinal mucosa to the 
reticuloendothelial system and blood. 
 
Paper II: 
Several studies have demonstrated stimulatory effect of Agaricus blazei Murill (AbM) on 
different immune cells. Dendritic cells are major directors of immune function and an 
important antigen presenting cell in the intestine. We wanted to examine the effect of AbM 
stimulation on cytokine release from monocyte-derived dendritic cells (MDDC). The cells 
were incubated with up to 10% of the AbM-based extract, AndoSan™, LPS (0.5 μg/ml) or 
phosohate-buffered solution (PBS) control. We found that the AbM extract promoted dose-
dependent increased levels of IL-8, G-CSF, TNFα, IL-1β, IL-6 and MIP-1β and induced a 
2- to 10-fold higher production than did LPS of G-CSF, TNFα and IL-1β. We conclude that 
stimulation of MDDC with an AbM-based extract resulted in increased production of 
proinflammatory, chemotactic and some Th1 type cytokines in vitro. 
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Paper III 
In this foremost in vivo study, the aim was to examine the effect of consumption in 
healthy individuals of the normal dose AbM-based extract, AndoSan™, for 12 days 
on expression of adhesion molecules CD11b, CD11c and CD62L and ROS in blood 
leukocytes. There was a significant increase of CD62L expression on monocytes and 
granulocytes from before (day 0) compared to (day 12) after daily AbM consumption. 
However, only minor alterations and no clear trend in the expression of CD11b and 
CD11c were detected. Intracellular ROS (mainly superoxide ion) were significantly 
reduced in these cells from days 0 to 12. After ingestion of high dose AbM-based 
extract (360 ml per day) for two days, gene expression by microarray analysis based 
on the affymetric gene chip platform was studied. There were no alterations in gene 
expression, whatsoever, including TLR2, CD11b, CD11c and CD62L. These results 
supported that oral intake of AbM exhibited a sligth anti-inflammatory effect in 
humans in vivo.  
 
Paper IV: 
Agaricus blazei Murill (AbM) has shown to reduce blood cytokine levels in healthy 
volunteers, pointing to an anti-inflammatory effect. The aim was to study whether 
AndoSan™ had similar effects on patients with ulcerative colitis (UC) and Crohn's 
disease (CD). Calprotectin, a marker for inflammatory bowel disease (IBD), was also 
measured. Patients with CD (n=11) and with UC (n=10) consumed 60 ml/day of 
AndoSan™. After 12 days baseline plasma cytokine levels in UC was significantly 
reduced for MCP-1 in unstimulated blood, in LPS-stimulated blood for MIP-1β, IL-6, 
IL-1β, IL-8, G-CSF, MCP-1 and GM-CSF. There were corresponding significant 
reductions in CD for IL-2, IL-17 and IL-8 and in LPS-stimulated blood for IL-1β, 
MIP-1β, MCP-1, IL-8, IL-17, GM-CSF and G-CSF. Baseline concentrations for the 
17 cytokines in the UC and CD patient groups were largely similar and elevated from 
~2 to ~7-fold. Calprotectin in feces was significantly reduced in the UC patients, but 
not in the CD patients. Plasma calprotectin was unaltered in both diseases. Ingestion 
of the AbM-based medicinal mushroom extract AndoSan™ by patients with IBD 
resulted in interesting anti-inflammatory effects as demonstrated by declined levels of 
pathogenic cytokines in blood and calprotectin in feces. 
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Data not shown 
In patients with UC (n=10) and CD (n=11) we examined, as for healthy individuals 
(paper I), levels of ROS and expression of adhesion molecules E-selectin (CD62L), ß2 
integrins (CD11b, CD11c) in granulocytes and monocytes at day 0 before and 12 
days after AndoSan™ consumption. There were no striking alterations in these 
parameters. Five of the patients with UC and CD, respectively, were randomly 
selected for microarray analysis prior to and at day 12 of AndoSan™ ingestion. We 
were not able to demonstrate altered gene expression, whatsoever, induced by the 
AbM-based mushroom extract.      
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General discussion 
 
The major finding in this thesis was that the Agaricus blazei Murill (AbM)-based mushroom 
extract AndoSan™ in humans, when ingested via the enteral route, exhibited an anti-
inflammatory effect in vivo contrary to a pro-inflammatory effect ex vivo and in vitro. 
 This anti-inflammatory effect is based on reduction in levels of several cytokines (IL-1ß, 
IL-2, IL-6, IL-8, IL-17, MIP-1ß, MCP-1, G-CSF, GM-CSF) in blood of healthy individuals 
(paper I) and patients with UC and CD (paper IV). Further, there was a reduction of the 
inflammatory marker calprotectin, mainly derived from granulocytes, in feces from patients 
with UC but not CD. In additon, the pro-inflammatory effect of AndoSan™ in vitro on 
monocyte derived DC was demonstrated by release of cytokines (IL-8, G-CSF, TNFα, IL-
1β, IL-6, MIP-1β and IFN) which was similar to previous studies in monocytes (5) and 
macrophages (95), but lesser in magnitude. As to the relevance of studying cytokines in 
blood in patients with IBD, the crucial finding, was that in nine (MIP-1ß, IFN , IL-6, 
TNF, MCP-1, IL-17, GM-CSF, IL-8 and IL-2) of the seventeen cytokines (paper IV), the 
levels were elevated from 
2 to 
7-fold compared with healthy individuals. Since 
autoimmune IBD exhibits systemic manifestations affecting the whole body, we took for 
granted that cytokine levels in blood mirrored those of the gut wall. There are three 
advantages from studying cytokine levels in blood instead of gut mucosa. Firstly, cytokines 
in blood are much easier accessible than gut located cytokines. Secondly, the 
representativity of a blood sample is presumably better than hitting the hot spots of the long 
gut mucosa. Thirdly, endoscopy with biopsies is bothersome and complications like 
bleeding and perforation may occur in a few patients. 
 The reduction of number of cytokines and their relative concentrations were more 
pronounced in healthy individuals than in IBD patients. This supported that key ingredients 
of the mushroom extract are absorbed into the gut wall also when confronted with an intact 
gut mucosa and prior to presentation to gut associated lymphoid tissue (GALT) like lymph 
nodes and Peyer’s patches. It is commonly believed that carbohydrates larger than 
monosaccharides are not absorbed from the human gut. However, in murine models (14;27) 
uptake of ß-1,3-glucans across the gut wall, probably by microfold cells (M cells), but also 
by DC (17), has been demonstrated. The ß-glucan may further be transported by DC to 
lymphocytes in GALT, but also circulated in blood rodents (45;87). Presumably, a similar 
mechanism is operating in humans for intestinal absorption of small and immunomodulatory 
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bioactive ß-glucan fragments into the lymphoid system and blood. A key to understanding 
the function of down-regulating the cytokine response in the gut wall, is probably the 
signals mediated by DC (89). Naïve DC secrete IL-10 which stimulate Treg cells which then 
inhibit Th1-, Th2- and Th17 cells and MФ responses. Conversely, more mature DC, 
presumably like in IBD (Fig. 7 and 8) and as demonstrated in vitro (paper II), secrete upon 
stimulation pro-inflammatory mediators such as TNF, IL-6, IL-8, IL-12 which create a 
chronic inflammatory cytokine driven response. In addition, AbM contains absorbable low 
molecular weight antioxidant substances (46), which down-regulate levels of ROS, which 
was seen regarding to superoxide anions in healthy individuals, but not in IBD patients. The 
reason for reduced superoxide anions may be related to reduction of IL-1ß because 
inhibitors of ROS reduce synthesis of this cytokine in macrophages (70). 
 The second major finding was that patients with UC had a significant reduction of fecal 
calprotectin after 12 days of AndoSan™ consumption, whilst calprotectin was unaltered in 
the CD patients (paper IV). Calprotectin is an abundant cytosolic protein mainly released 
from neutrophils (97), and is considered a reliable surrogate marker of disease activity in 
IBD (30) when released to feces. Reduction in fecal calprotectin has been detected parallel 
with reduced degree of inflammation in CD, but the reported initial calprotectin values were 
much higher (~15-fold) (106) and from more seriously affected patients than in this study 
(paper IV). The limited period of AndoSanTM ingestion and the difference in disease 
severity may contribute to explain the lack of effect on fecal calprotectin levels in our CD 
patients. The unaltered levels of plasma calprotectin by AbM consumption, indicated that 
the effect of AndoSanTM on that parameter was on granulocytes located in the colonic 
mucosa. During active inflammation, neutrophils infiltrate the lamina propria, the mucosal 
epithelium and form crypt abscesses that resolve during periods of remission (49). The IBD 
patients also spontaneously reported reduction of bowel movements after a few days of 
AndoSanTM consumption, that may in part be related to reduction of  fecal calprotectin. 
 We were not able to demonstrate  convincing anti-inflammatory effects in blood 
concerning altered expression of adhesion molecules E-selectin (CD62L) and ß2 integrins 
(CD11b, CD11c) in granulocytes and monocytes in healthy individuals (paper III) and IBD 
patients (data not shown). However, the slight increase in E-selectin expression on 
granulocytes and monocytes in vivo as a consequence of AndoSanTM consumption in healthy 
individuals, may imply an anti-inflammatory effect. Neutrophils in knock-out mice (94) that 
lack the ability to shed E-selectin exhibited reduced migration towards a gradient of 
inflammatory chemokines, which suggested that L-selectin shedding is required for efficient 
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transendothelial migration. Concerning ROS, there was a slight, but significant reduction of 
DHE expression, mainly reflecting superoxide ions, in granulocytes after 12 days of 
AndoSan™ ingestion in healthy individuals (paper I), but not in IBD patients (data not 
shown). Accordingly, an anti-inflammatory effect by these parameters could generally not 
be demonstrated in IBD patients and only to a minor extent in healthy individuals 
concerning reduction of ROS and increase of E-selectin. Also, we were not able to detect 
any alteration of gene expression in healthy individuals after two days use of high dose (360 
ml/day) AndoSanTM (paper III) and in IBD patients (data not shown) after long-term low 
dose (60 ml/day) consumption of the AbM mushroom extract AndoSan™, respectively. 
 Thus, the convincing anti-inflammatory effects demonstrated in this thesis in vivo are 
based on the impact of reductions in concentrations of cytokines and fecal calprotectin. 
 The effect of the AbM mushroom extract AndoSan™ on cells of innate immunity, as 
described in the introduction, is for ß-glucan by way of interaction of  PRR on monocytes, 
MФ, DC, NK cells and granulocytes. Prominent PRR are TLR 2 (103), dectin-1 receptor 
(13), the lectin binding site for ß-glucan in CR3 (104) and possibly CR4 (4). Effects of these 
receptors  include induction of  NF-B mediated pro-inflammatory cytokines (TLR2, 
dectin-1 receptor) and binding and ingestion of microorganisms as well as degranulation 
and respiratory burst (CR3 and CR4) (84). The AbM mushroom extract contains soluble and 
larger insoluble ß-glucan fragments of several μm that may be responsible for biologic 
activites. Concerning anti-tumor activity in rodents (27;108), high molecular weight 
polysaccharide fractions (100-200 kDa) were most active in vivo, whereas small molecular 
fragments (0,5-10 kDa) showed no activity. Although AbM is the dominating mushroom 
(82%) of the AndoSan™ extract compared to H. Erinacium (15%) (57) and G. frondosa 
(3%) (1), biologic activites exerted by the latter two mushroom, isolated or in synergy, must 
be kept in mind. 
 Increased cytokine levels in serum have only been reported for IL-6 (44) and TNF (66) 
in patients with UC and CD and for MIP-1ß in the former disease for UC (90). We report 
the novel finding of as many as six cytokines (IL-2, IL-8, IL-12, IL-17, MCP-1, GM-CSF), 
in addition to three known cytokines (MIP-1ß, TNF, IL-6), being similarly elevated  in UC 
and CD. These findings challenge the notion that UC is a Th2 cell mediated disease and that 
CD is a Th1 cell mediated disease, since the same type of cytokines were elevated in both 
diseases (paper IV). As could be expected, the anti-inflammatory effect of AndoSan™ was 
easier to detect in healthy individuals since there was a reduction in as many as five 
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cytokines (IL-1ß, TNF, IL-2, IL-6, IL-17) in unstimulated blood versus one cytokine 
(MCP-1) in UC and three cytokines (IL-2, IL-8, IL-17) in CD. On the other hand, after LPS 
stimulation ex vivo of  harvested blood, the corresponding number of additional cytokines 
reduced were four in healthy individuals, six in UC and five in CD. Using LPS stimulation, 
this demonstrated a considerable decrease of the intracellular stores of the crucial cytokines 
that substantiated the anti-inflammatory effect of the mushroom extract. Caution must be 
made concerning measurements of MIP-1ß after LPS stimulation of blood due to values out 
of range despite sample dilution 1/10. 
 The two cytokines which were reduced in both healthy individuals and IBD patients were 
IL-1ß and chemokine G-CSF, which are both crucial contributors for inflammation. 
Interestingly, in CD the Th1 cell cytokine IL-2 and the Th17 cell cytokine IL-17, which are 
considered pathogenic cytokines, were reduced with and without LPS stimulation (54;61). 
For UC, none of  the Th2 cell cytokines (IL-4, IL-5, IL-13) were reduced, although a clear 
overall anti-inflammatory effect was obtained. 
 One healthy volunteer was excluded from the study (paper I) due to reoccurrence of 
herpes labialis during use of low dose AndoSanTM, but other potential adverse effects were 
not discovered. Blood parameters testing pancreatic-, liver- and renal function were 
unaltered and within the normal range. It has been suggested that several months of AbM 
consumption was the possible cause of hepatic dysfunction, in three cancer patients, other 
than chemotherapy, one of whom died from hepatic failure (65). However, intake of AbM 
extract for 12 months normalized liver function in four patients with chronic hepatitis B 
(43). Moreover, one week intake of AbM in hepatitis C patients had no adverse effects on 
liver function (35). When considering the thousands of people consuming AbM, this extract 
seems harmless and definite hepatotoxicity has not been clearly demonstrated (65). 
 One objection to the cytokine studies in humans can be that no placebo group was 
included. Accordingly, the participants were their own controls and the comparison was 
made between before and after consumption of AndoSanTM. Especially psychosomatic 
factors could contribute to a placebo effect independent of the AbM mushroom extract. 
However, since an anti-inflammatory effect was found in three groups of people with and 
without disease, the results must be interpreted as valid.    
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Conclusion  
 
 In conclusion, we have in this thesis demonstrated an anti-inflammatory effect in vivo as 
measured by reduced release of cytokines to blood  and calprotectin to feces as a 
consequence of ingestion of the AbM-based mushroom extract AndoSanTM. This effect 
which dampened an inflammatory response, is particularly relevant for patients with IBD 
and may partly be ascribed to development of  tolerance mediated by the DC through 
stimulation of Treg cells.      
 
 
Future perspectives 
 
Patients with IBD are dependent on surgical and/or medical treatment for relief of 
symptoms. The anti-inflammatory effect of the AbM-based mushroom extract AndoSanTM 
may be of potential benefit in these patients as a support therapy, thereby reducing 
dependence on traditional treatment. However, before AndoSanTM may be introduced as a 
support therapy, randomized studies comparing this mushroom extract with placebo have to 
be performed. Such studies should also include intake of AndoSanTM for longer time 
intervals.      
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Abstract 
 
Background: Oral intake (60 ml daily) over 12 days in eight healthy volunteers of an 
immuno-stimulatory extract based on the medicinal mushroom Agaricus blazei Murill 
(AbM), reduced  monocyte and granulocyte release of mainly pro-inflammatory 
cytokines in vivo,  suggesting an anti-inflammatory effect. In this foremost in vivo study, 
the aim was to examine the effect of such AbM consumption on expression of adhesion 
molecules CD11b, CD11c and CD62L and on production of reactive oxygen species 
(ROS) in leukocytes.  
Methodology/Principal Findings: As shown by flow cytometry, there was a significant 
increase of CD62L expression on monocytes and granulocytes from before (day 0) 
compared to 12 days after daily AbM consumption. However, only minor alterations and 
no clear trend in the expression of CD11b and CD11c were detected. Intracellular ROS 
(mainly superoxide ion) were significantly reduced in these cells from days 0 to 12. 
Conclusions/Significance: These results support that oral intake of AbM exhibits an 
anti-inflammatory effect in humans in vivo.   
 
Key words: monocyte; granulocyte; ROS; adhesion molecules 
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Introduction  
 
The Agaricus blazei Murill mushroom (AbM) (jap.: Himematsutake) of the 
Basidiomycetes family grows wild in the Piedade area outside of São Paulo, Brazil. 
People in this area have traditionally used AbM as a health food ingredient. The 
frequency of serious diseases like atherosclerosis, hepatitis, hyperlipidemia, diabetes and 
cancer 1 were lower in Piedade than in neighbouring regions, supposedly due to the 
AbM intake.  In 1966 the mushroom was taken to Japan and introduced to the health food 
market. AbM has also been subjected to an increasing research effort, especially since the 
early 1980s. Other interesting medicinal Basidiomycetes mushrooms that have been 
studied are Grifola frondosa (Gf) (Maitake) 2 and Hericeum erinaceum (He) 
(Yamabushitake) 3.  
    AbM, like Gf, is rich in immunostimulatory mixture of  β(1-3)-, (1-4) and β(1-6)-D-
glucans with antitumor activity 4, probably secondary to modulation of NK-cells 5 
and monocytes/macrophages of native immunity 6-8 . 
   In vitro AbM stimulates mononuclear phagocytes to secrete nitric oxide 9 and pro-
inflammatory cytokines like IL-1, IL-6, and TNF, and chemokine IL-8 9, 10. The 
effects are probably mediated by binding of sugars in AbM to TLR-2 11, but also to 
dectin-1 12 and the lectin-binding site of CD11b/18 13 and possibly CD11c/18 14. 
Gene microarray expression analysis of promonocytic THP-1 tumor cells 15 supported 
these results since stimulation with AbM upregulated genes strongly for IL-1β and IL-8, 
moderately for TLR-2 and MyD88 but not for TLR-4. On the other hand, daily 
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consumption of 60 ml of AbM for seven days in patients with chronic hepatitis C 16, 
had no effect in vivo on expression of these genes in blood cells. 
   Recently, we reported that AbM stimulation of whole blood ex vivo 17 stimulated the 
release of all the 17 different cytokines, chemokines and leukocyte growth factors tested. 
The cytokines were pro-inflammatory (IL-1, IL-6, TNF), anti-inflammatory (IL-10), 
pleiotropic (IL-7, IL-17) and of the Th1- (IL-2, IFN, IL-12) and Th2-types (IL-4, IL-5, 
IL-13). In addition, chemokines IL-8, MIP-1, MCP-1 and leukocyte growth factors G-
CSF and GM-CSF were also studied. On the other hand, when blood were harvested from 
volunteers prior to and 12 days after their daily intake (60 ml) of AbM, there was in vivo 
either a significant reduction in cytokine levels for IL-1, TNF, IL-6, IL-2 and IL-17 or 
unaltered levels of the remaining twelve factors.  This points to a stabilising and anti-
inflammatory effect of AbM in vivo when given via the oral route.  
   Ex vivo studies 18 in whole blood demonstrated that AbM decreased the expression of 
adhesion molecule CD62L (L-selectin) and increased the expression of the 2 integrin 
CD11b on monocytes and granulocytes. These molecules are cruicial for respectively 
rolling and adherence to endothelial cells 19,20, and prerequisites for the ultimate 
transcapillary diapedesis of leukocytes to inflammatory foci in order to attack 
microorganisms.   
   Especially granulocytes, but also monocytes, generate reactive oxygen species (ROS) 
such as O2.¯ , H2O2,  .OH  and ONOO¯ upon stimulation during phagocytosis, which 
damages ingested microorganisms by peroxidation of lipids, proteins, and nucleic acids, 
and nitrosylation of proteins 21,22. AbM stimulation of whole blood ex vivo 18 had 
no effect on ROS production detected by the dihydroethidium (DHE) probe (mainly 
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reflecting superoxide anion), neither in granulocytes nor monocytes. However, a slight 
increase in ROS detected by the dihydrorhodamine 123 (DHR) probe (mainly detecting 
peroxynitrite), was evident in granulocytes upon stimulation with the two highest 
concentrations (10%, 15%) of AbM. 
   Accordingly, the next step was also to study in vivo the effect on adhesion molecule 
expression (CD62L, CD11b, as well as the 2 integrin CD11c) and intracellular ROS 
levels in human leukocytes after oral intake of AbM over days in healthy volunteers.      
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Results 
 
Effect of AbM on expression of adhesion molecules in whole blood ex vivo   
The expression of CD11c/CD18 (Fig. 1c) increased and peaked already at the lowest 
concentration of AbM (0.1%) and was more than two-fold higher for monocytes than for 
granulocytes.  
   Increase in CD11b expression (Fig. 1a) and a decrease in CD62L expression (Fig. 1b) 
on the surface of granulocytes and monocytes after stimulation of whole blood with AbM 
in concentrations from 0.1 to 10% were also demonstrated. The increase in CD11b was 
more pronounced for granulocytes than for monocytes, and reached a plateau at a lower 
concentration of AbM in former cell type (0.5% versus 2%). The reduction of expression 
of L-selectin (Fig. 1b) (CD62L) was stronger in monocytes than in granulocytes and 
occurred at lower concentration of AbM (0.1% versus 2%), with nadir levels at 5% and 
of 10%, respectively.  
    
Effect of AbM on expression of adhesion molecules in whole blood in vivo 
   In eight individuals using AbM, in doses of  20 ml x 3 daily for 12 days, there was a 
significant reduction of CD11b expression in monocytes from day 0 to day 2 (Fig. 2a), 
and the levels fluctuated significantly throughout the experimental period. In 
granulocytes, however, there was a significantly higher amount of CD11b (Fig. 2a) 
compared with the monocytes, but without any significant alterations during the 
experimental period.   
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    Concerning CD11c expression (Fig. 2b) and contrary to CD11b, the levels were 
significantly higher in monocytes than in granulocytes. However, only for granulocytes 
the levels increased from day 0 to day 5 and varied significantly during the experimental 
period only for granulocytes. There was a significant increase from day 0 to day 12 
regarding expression of CD62L (Fig. 2c), and it was more pronounced for monocytes  
than for granulocytes.     
   Fifteen healthy individuals used high dose of AbM (120 ml x 3) for 2 days. When the 
cells were analysed for expression of CD11b, CD11c and CD62L prior to (day 0) and 
after intake of AbM (days 1 and 2), there were no significant alteration whatsoever at any 
time points tested (data not shown). However, when the cells in whole blood were 
stimulated for one hour with LPS (1 g/ml) ex vivo , an expected and comparable 
increase in CD11b and CD11c and decrease in CD62L was demonstrated (data not 
shown), both before and after intake of AbM in low dose for 12 days and high dose for 2 
days, respectively.  
 
Effect of AbM on ROS production in whole blood in vivo  
   The intracellular levels of ROS detected by the DHE-monitored assay (mainly 
reflecting superoxide anion) in harvested cells from eight healthy volunteers ingesting 
AbM, exhibited a significant reduction from prior to (day 0) and 12 days after intake 
(Fig. 3a).  Moreover, the levels of ROS were higher in monocytes compared with 
granulocytes.   Analysis of ROS detected by the DHR probe (mainly reflecting 
peroxynitrite ions), revealed some alterations throughout the experiment for monocytes 
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(p=0.04) but no significant difference for either cell type when comparing levels of ROS 
from start (day 0) till end of the experiment (day 12) (Fig. 3b). 
   Finally, the high concentration of AbM (120 ml x 3 daily) was used for a short period 
of  2 days in 15 healthy individuals. In this experimental set-up the results were unaltered 
for ROS detected by DHE and DHR in blood, both prior to (day 0) and after intake of 
AbM for 1 and 2 days (data not shown).  PMA stimulation of harvested whole blood ex 
vivo for 60 min. from the volunteers prior to or after consumption high or low dose AbM 
for 2 and 12 days, respectively, revealed comparable increase of ROS levels (data not 
shown).  
 
Effect of AbM on gene expression  
   In three healthy middle-aged males consuming high dose AndoSanTM  for 2 days there 
were no differential expression of mRNA for the following genes; TLRs- 2 and -4, 
CD11b (gene symbol ITGAM), CD11c (ITGAX), CD62L (SELL) and My88.  
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Discussion  
 
 
The main aim of this study was to examine the effect of oral intake of the AbM based 
mushroom extract in healthy volunteers on expression of adhesion molecules and ROS 
production in monocytes and granulocytes in whole blood in vivo.   
   Previously 18 and more extensively in the present study also including CD11c, we 
demonstrate that AbM stimulation of whole blood ex vivo dose-dependently increased the 
levels of CD11b and CD11c expression and decreased the levels of C62L expression on 
the surface of monocytes and granulocytes (Fig. 1). From these results we propose that 
the AbM-stimulated leukocytes are more prone to phagocytosis via complement receptors 
C3 (CR3) (CD11b/CD18) [23] and C4 (CR4) (CD11c/CD18) 14, the glucan- 24 and 
the dectin 1 receptor 12.  Moreover, modulation of the leukocyte adhesion molecule 
profile 20,25 contributes to events necessary for rolling, firm adhesion and 
extravasation of the leukocytes through the endothelial cell layer to inflammatory foci. 
The inverse relationship between CD11b/CD11c and CD62L expression has also been 
reported 26 in a similar experimental set-up, in which whole blood was stimulated with 
meningococcal LPS.  
   On the other hand, when these adhesion molecules were analysed in vivo (Fig. 2) 
during a period of 12 days with daily intake of 60 ml of the mushroom extract, there were 
only minor alterations in expression of CD11b and CD11c on both on granulocytes and 
monocytes. However, concerning CD62L expression on the surface of the granulocytes 
and monocytes, there was a significant increase from baseline (day 0) to 12 days after 
daily consumption of AbM (Fig. 2c). This was contrary to the decrease in CD62L 
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expression demonstrated ex vivo (Fig. 1c) and explained by shedding [27] from the 
plasma membrane 28. Studies in knock-out mice, which lack the ability to shed L-
selectin from neutrophilic granulocytes 29, showed reduced migration towards a 
gradient of inflammatory chemokines. This suggests that L-selectin shedding is required 
for efficient transendothelial migration. Accordingly, higher levels of L-selectin on the 
surface of monocytes and granulocytes in vivo after consumption of AbM might stabilise 
or reduce this process, which implies an anti-inflammatory effect of AbM in the body. 
The lack of effect on levels of adhesion molecules after intake of high daily doses of 
AbM (360 ml/day) for 2 days, was probably due to the short duration of this experiment. 
    Regarding the generation of ROS  of whole blood ex vivo 18, only a limited increase 
in mainly ONOO¯  (DHR probe) but not O2.¯  (DHE probe) was detected in granulocytes, 
upon stimulation with high concentrations of AbM (10% and 15%).  However, when 
studying ROS in vivo, daily intake of low dose AbM resulted in a significant reduction in 
mainly O2.¯  at day 12 (Fig. 3a). This again points to an anti-inflammatory effect.  
Increased occurrence of cancer with age might in part be explained by damage inflicted 
by ROS-induced generation of oxidative stress, giving aberrant DNA methylation 
patterns in normal cells 30,31. Accordingly, the AbM induced reduced production of 
ROS, demonstrated in vitro 32 and herein in vivo, agrees with the proposed cancer-
protecting properties of AbM 8. Recently, we reported 17 that the levels of 17 
different cytokines (especially pro-inflammatory and anti-inflammatory cytokines), 
chemokines and growth factors increased by AbM stimulation of whole blood ex vivo. On 
the other hand, intake of low dose of AbM over 12 days in vivo resulted in significant 
reduction, from day 0 to day 12 in five of these foremost pro-inflammatory cytokines (IL-
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1, TNF, IL-6, IL-2, IL-17). The most pronounced reduction in vivo was for IL-1, 
which is very interesting because inhibitors of ROS (such as N-acetylcysteine) have been 
reported to block IL-1 production in macrophages 33.  Accordingly, since AbM also 
contain low molecular weight antioxidant substances 34, this could contribute to the 
explanation of a combined reduction of ROS and IL-1 production in monocytes and 
granulocytes in vivo.  
   In this study, it was pertinent to examine whether genes for TLRs-2 and -4, CD11b, 
CD11c, CD62L as well as My88 were differentially expressed in blood cells in vivo as a 
consequence of AbM consumption in healty individuals.  Similar to a recent in vivo study 
on chronic hepatitis C patients consuming low dose AbM for 7 days 19 differential 
effects were not demonstrated on expression of these genes as measured by mRNA in 
volunteers consuming high dose AbM for 2 days. The effect of AbM in vivo does not 
seem to be mediated by TLRs, especially since MyD88 expression also was unaltered, 
which is critical for signaling from all TLRs except TLR-3 35. However, when 
monocytic tumor like cells (THP-1) are AbM stimulated in vitro forementioned genes are 
upregulated except TLR-4 15, as well as genes for pro-inflammatory cytokines IL-1β 
and IL-8.   
   The discrepant results obtained with AbM on expression of adhesion molecules and 
generation of ROS in monocytes and granulocytes ex vivo and in vivo, demands 
consideration. There might be a very limited absorption of large and bioactive β-glucan 
fragments across the intestinal mucosa to the reticuloendothelial system and to the blood, 
which excludes their potential prominent stimulatory effect on expression of adhesion 
molecules and cytokine release as demonstrated ex vivo 17,18. In murine models, 
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however, uptake of β-1,3-glucans by gastrointestinal macrophages and shuttling to the 
reticuloendothelial system and bone marrow has been demonstrated 36. As to anti-
tumor activity 36,37, high molecular weigth polysaccharide fractions (100-200 kD) 
were most active in vivo, whereas  smaller molecules (0.5-10 kD) exhibited no activity. 
Increased uptake of AbM from the gut and enhanced antitumor activity in a myeloma 
mouse model, has been shown after encapsulation of it AbM β-glucans in marine 
phospholipids 38. On the other hand, β-glucans could have had an additional indirect 
effect locally in the intestines by stimulating immune cells like monocytes or dendritic 
cells  in Peyer’s patches. 
      We have hereby shown that AbM consumed over days by healthy volunteers increase 
in vivo the expression of L-selectin and reduce transiently that of CD11b and markedly 
reduce the production of ROS in monocytes and granulocytes in whole blood. Together 
with the reported 17 in vivo reduction in levels of mainly pro-inflammatory cytokines in 
identical experimental set-up, our results indicate a stabilising and anti-inflammatory 
effect of AbM in vivo.  We plan to study whether AbM can have a clinical effect through 
normalization of these inflammatory parameters in vivo in patients with inflammatory 
bowel disease.   
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Conclusions  
 Oral intake over 12 days in eight healthy volunteers of an AbM based immuno-
stimulatory mushroom extract resulted in reduction of ROS in monocytes and 
granulocytes. An increase in expression of L-selectin occurred on these cells, whilst 
levels of adhesion molecules CD11b and CD11c largely were unaltered. Together with 
reported 17 reduction in vivo of pro-inflammatory cytokines, the results strengthen the 
assumption of a stabilizing and anti-inflammatory effect of this mushroom extract. The 
impact of AbM on patients with inflammatory bowel disease will be tested.  
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Materials and Methods  
 
Reagents and antibodies 
   The mushroom extract (AndoSanTM) used in our experiments was obtained from ACE 
Co., Ltd., Gifu, Japan. It was stored at 4°C in dark bottles and kept sterile. This 
Basidiomycetes mushroom extract is a commercial product and its exact contents a 
business secret, part of which has not been revealed until very recently. The AbM mixed 
powder contains per 100 g the following constituents: moisture 5.8 g, protein 2.6 g, fat 
0.3 g, carbohydrates 89.4 g of which -glucan constitutes 2.8 g, and ash 1.9 g. The 
AndoSanTM extract contains 82.4% of Basidiomycetes mushroom derived from Agaricus 
blazei Murill, 14.7% from  Hericium erinaceum and 2.9% from Grifola frondosa, and its 
final concentration was 340 g/l. The amount per litre of the extract for sodium was 11 
mg, phosphorous 254 mg, calcium 35 mg, potassium 483 mg, magnesium 99 mg and zinc 
60 mg.  The LPS content of AndoSanTM were found using the Limulus amebocyte lysate 
test (COAMATIC Chroma-LAL; Chromogenix, Falmouth, MA, USA) with detection 
limit 0.005 EU/ml (1 EU=0.1 ng/ml), to be a miniscule concentration of <0.05 pg/ml 
17. AndoSanTM had been heat-sterilized (124C for 1 h) by the producer. LPS was from 
Escherichia coli (E. coli 026:B6) (Sigma Co., St. Louis, MO, USA). 
   Fluorescein isothiocyanate (FITC)-conjugated mouse monoclonal antibody against 2 
integrin CD11b was obtained from Sigma (10 μl/test). The 2 integrins are classified 
according to their α and  subunits as CD11/CD18 molecules. They are composed of 
identical  subunits (CD18) and different  subunits (CD11b/Mac-1 and CD11c/ 
gp150,95). Phycoerythrin (PE)-conjugated mouse monoclonal antibodies against CD62L 
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(L-selectin), FITC-conjugated mouse anti-CD11c (20 μl/test) and isotype IgGs for 
CD62L and CD11b, and CD11c were obtained from Becton Dickinson, San José, CA, 
USA and Sigma Co., St. Louis, MO, USA, respectively. Dihydroethidium (DHE) was 
obtained from Sigma, and dihydrorhodamine 123 (DHR) from Molecular Probes, Leiden, 
The Netherlands.  
 
Experimental design 
Ex vivo experiments 
   Venous EDTA-blood was collected from six healthy volunteers (four men) with median 
age 38.5 (range 37-61) years. In order to study the expression of leukocyte adhesion 
molecules (CD11b, CD11c, CD62L), aliquots of fresh whole blood (400 l) was 
incubated with 0.1, 0.5, 2.0, 5.0, 10.0 or 15.0 % (final concentration) of sterile 
AndoSanTM for 60 min at 37°C. Positive (LPS 1 µg/ml) or negative (phosphate buffered 
saline, PBS) controls were included.   
 
In vivo experiments 
    Five healthy men and five healthy women, of median age 30.5 (range 26-51) years, 
volunteered to participate in the study of oral intake of low dose AndoSanTM; 20 ml thrice 
daily for 12 days. The dose of a total of 60 ml of the mushroom extract per day was 
chosen because this was the dose recommended by the manufacturer and regularly used 
for AndoSanTM as a health product. The time interval between each dose should be from 
6-10 hours. Participants were asked to avoid mushroom-containing foods for 3 days prior 
to and during the experimental period. Three women used contraceptive drugs, one of 
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whom also 100 mg x 1 of iron on days 0, 7, 8 and 9, and another woman ate a pizza with 
mushrooms on day 1 and used medication against migraine (rizatriptan, rapitab, 
ibuprofen, paracetamol, phenazone-caffeine) on days 0, 5, 6 and 7. One female 
participant stopped the intake of AndoSanTM due to reoccurrence of localized labial 
eruption, probably her known herpes simplex labialis. One male participant was for 
practical reasons unable to give the last blood sample. Accordingly, two of the 10 
participants were not included in the complete analysis of the results. None of the 
participants reported trouble with intake of AndoSanTM due to taste or volume.    
   Venous blood EDTA (total 10 ml) was collected on day 0 immediately prior to intake 
of the mushroom extract and on days 1, 2, 5, 8 and 12, and analysed for adhesion 
molecules (CD11b, CD11c, CD62L) and reactive oxygen species (ROS). The blood 
samples were each time analysed for hemoglobin, hematocrite, mean cellular volume, 
mean cellular hemoglobin, reticulocytes, immature reticulocytes, leukocytes including a 
differential count of neutrophils, basophils, eosinophils, lymphocytes and monocytes. C-
reactive protein (CRP), thrombocytes, urea, creatinine, bilirubin, aspartate 
aminotransferase, alanine aminotransferase, lactate dehydrogenase, -glutamine 
transferase, alkaline phosphatase, and pancreatic amylase.  
   Same type of in vivo experiment was performed in fifteen healthy persons (8 women) 
of median age 36 (range 23-55) years, but the dose of AndoSanTM was high (120 ml 
thrice daily) and the experiment limited to two days. One woman used daily a 20 mg 
tablet of esomeprazole as anti-secretory medication. Six of these 15 persons had 
previously also participated in the experiment using low dose AndoSanTM. By giving 720 
ml of the extract to individuals of weight 60-80 kg during 2 days, the amount of 
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AndoSanTM taken was comparable to that  given orogastrically (0.2 ml AndoSanTM) to 
mice 23 (18-20 g) prior to experimentally infecting the animals with fecal bacteria for 
lethal peritonitis, which was significantly reduced by AndoSanTM pretreatment. Thus, the 
notion was that use of comparable amounts of the mixed mushroom extract relative to 
body weight (9-12 ml/kg and 10-11 ml/kg in man and mouse, respectively), would be a 
rational strategy for observing beneficial or possible side (toxic) effects in humans.   
   All the participants in the in vivo and ex vivo experiments denied regular smoking or 
intake of medication, unless otherwise stated.  
   As recently reported 17, there were no alterations whatsoever in any of the 
hematological parameters tested during the experimental periods of 12 days and 2 days 
with low and high dose AndoSanTM, respectively  
 
Preparation of blood leukocytes for flow cytometric analysis 
    For flow cytometric analysis of leukocyte adhesion molecules, 50 μl of whole blood 
(unstimulated or stimulated with AbM or LPS) in 12x75 mm polystyrene test tubes 
(Falcon no. 2052) was mixed with monoclonal antibodies against CD11b (10 μl), CD11c 
(10 μl) or CD62L (20 μl) using Vortex mixer and then incubated on ice for 30 min. Blood 
with 10 μl PBS served as autofluorescence control. In addition, controls containing 
antibody-matched isotype IgGs were used. No evidence of significant non-specific (Fc 
receptor-mediated) binding of IgG to AbM-LPS-stimulated granulocytes/monocytes was 
demonstrated (data not shown).  
   After finishing incubation with anti-CD11b/CD11c/CD62L or DHE/DHR (vide infra), 
respectively, erythrocytes were lysed. For lysis of erythrocytes, 1.5 ml of a lysis buffer 
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containing 155.5 mmol/l of NH4Cl, 1 mmol/l of NaHCO3 and 0.109 mmol/l of EDTA-
Na3 was applied for 15 min at room temperature in the dark.  
   The samples were then centrifuged at 300 g for 5 min at 4˚C, and the cells washed once 
in 2 ml of PBS and finally resuspended in 0.5 ml of 1% w/v paraformaldehyde (Merck, 
Darmstadt, Germany). The samples were kept cold and dark during the whole procedure 
as well as during the storage before analysis. 
   Flow cytometric analysis of intracellular ROS in leukocytes (whole blood), including 
100 ng/ml phorbol myristate acetate (PMA) (positive control) and PBS (negative 
control), was performed with aliquots of 50 μl of whole blood mixed with 10 μl of DHE 
(mainly reflecting superoxide anion) or 10 μl of DHR (mainly reflecting peroxynitrite 
and hypochlorous acid), both to a final concentration of 5 μmol/l. After incubation (5% 
CO2 and 95% humidified air) for 60 min at 37˚C, erythrocytes were lysed and leukocytes 
were washed and fixed, as described above. The production of ROS in leukocytes could 
be evaluated due to the transformation of the probes DHE/DHR from nonfluorescent to 
fluorescent compounds by the oxidative burst intermediates within the cells.  
 
Flow cytometric analysis and data collection 
   The labeled samples were analyzed within 24 h in a FACSortTM flow cytometer 
(Becton Dickinson). The flow cytometer was equipped with a 488 nm Argon laser and 
CellQuestTM Software (Becton Dickinson). Ten thousand events were collected from 
each sample. The leukocyte subpopulations, monocytes and granulocytes, were identified 
by their light scatter characteristics, enclosed in electronic gates, and separately analyzed 
for fluorescence intensity. The results were expressed as the mean fluorescence intensity 
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(MFI) of 10,000 cells. It should be noted that the average MFI values after in vitro PMA 
stimulation of monocytes and granulocytes were 2.6 times and 74 times higher (DHE 
probe) and 6.1 times and 167 times higher (DHR probe), respectively, than the MFI 
values at baseline levels. The intra-assay coefficient of variation (CV) was <5% in 
unstimulated and <10% in PMA-stimulated samples. 
 
Microarray analysis 
   Studies on gene expression by microarray analysis (www.affymetrix.com) in three of 
the males (ages 37, 50 and 51 years) consuming the high dose AndoSanTM  for 2 days, 
were also performed. Blood was harvested in PAX gene tubes specifically designed to 
preserve RNA from blood for microarray experiments prior to (day 0) and after 2 days of 
AndoSanTM  consumption. The PAX gene tubes were frozen and kept at -20 ºC until 
extraction with the PAXgene Blood RNA Kit (Qiagen) according to the manufacturer’s 
recommendation.  2.5 µg of total RNAs were subjected to One Cycle cDNA Synthesis 
Kit following the manufacturer´s (Affymetrix) recommended protocol for gene 
expression analysis. Biotinylated and fragmented cRNA (15 µg) was hybridized to the 
Affymetrix  HG U133 Plus 2.0 Array,  representing 47000 transcripts  for  38500 well-
characterized human genes. The signal intensities were detected by Hewlett Packard 
Gene Array Scanner 3000 7G (Hewlett Packard, Palo Alto, CA). All data is MIAME 
compliant and the raw data has been deposited in a MIAME compliant database at GEO 
under accession number xxxxxxxxxx, as detailed on the MGED Society website 
http://www.mged.org/Workgroups/MIAME/miame.html. 
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Statistical analysis of gene expression profiling 
   The 6 scanned images were processed using GCOS 1.4 (Affymetrix). The CEL files 
were imported into Array Assist software (v5.2.0; Iobion Informatics LLC, La Jolla, CA) 
and normalized using the PLIER (Probe Logarithmic Intensity Error) algorithm in Array 
Assist to calculate relative signal values for each probe set. In order to filtrate for low 
signal values, the MAS5 algorithm in Array Assist was used to create a dataset of 
Absolute Calls, showing the number of present and absent calls for each probe set. The 
filtration was performed by eliminating probe sets containing ≥4 absent calls across the 
data set, resulting in a reduction of probe sets from 47,000 to 28,188. For expression 
comparisons of different groups, profiles were compared using paired t-test. The results 
are expressed as fold changes (FC), e.g. ratio of of the mean signals between 
consumption of high dose AndoSanTM  for 2 days and immediately prior to AndoSanTM 
consumption. Gene lists were generated with the criteria of p<0.05 and FC of ≥|2|. 
 
Statistics 
All measurements were based on duplicates from six donors when blood was sampled for 
the ex vivo experiments. For the in vivo experiments blood was sampled from eight 
donors (duplicates) prior to and after intake of AndoSanTM on days 1, 2, 5, 8 and 12, or 
on days 1 and 2, in low and high dose experiments, respectively. Data are presented as 
mean ±standard error of the mean (SEM). Differences in levels of adhesion molecules 
(CD11b, CD11c, CD62L) and ROS were, after passage of normality test, assessed with 
parametric analysis of variance (ANOVA) for paired data with Dunn’s test comparing the 
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control value with the values after stimulation ex vivo or in vivo. In order to compare 
whether the levels of parameters were significantly different between monocytes and 
granulocytes, a two-tailed paired t-test was used.  The instat for WindowsTM statistics 
software package (Graphpad Software, San Diego, USA) was used and p values of or 
below 0.05 were considered statistically significant.  
             
Ethics 
   The study was approved by the regional ethics committee (full name: REC for Health 
South-Eastern HF of Norway) of the ethics committee/institutional review boardand 
followed the guidelines of the Helsinki declaration. The participants were informed also 
in written form and signed an agreement of consent for participation in the study.  
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Supporting Information  
 
Figure legends 
 
Figure 1   Ex vivo expression of surface adhesion  molecules on leukocytes.  
Expression ex vivo of the cell surface adhesion molecules CD11b (a), CD11c (b) and 
CD62L (c), measured as the mean fluorescence intensity (MFI), in leukocytes without 
and with AbM in increasing concentrations. Filled and open columns represent 
monocytes and granulocytes, respectively. Data are presented as mean values  SEM 
from six healthy individuals. Significant differences from the control were set at levels of 
p<0.05 (*), p<0.01 (**) and p<0.001 (***).  
 
Figure 2   In vivo expression of surface adhesion molecules on leukocytes.  
Expression in vivo of the cell surface adhesion molecules CD11b (a), CD11c (b) and 
CD62L (c) in monocytes and granulocytes in healthy volunteers using 60 ml of AbM 
daily for 12 days. Data are presented as mean values  SEM from eight healthy 
individuals. Significant differences from the control (day 0) were at p<0.05 (*). 
 
Figure 3   In vivo generation of ROS in leukocytes. Reactive oxygen species (ROS) 
generation in vivo in monocytes and granulocytes, detected by the DHE probe (a) and the 
DHR probe (b), in healthy volunteers using 60 ml of AbM daily for 12 days. Data are 
presented as mean values  SEM from eight healthy individuals. Significant differences 
from the control (day 0) were at p<0.01 (**). 
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